PFIZER INC. These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert. GENERIC DRUG NAME AND/OR COMPOUND NUMBER Tofacitinib / CP-690550 PROTOCOL NO.: A3921091 PROTOCOL TITLE: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of 2 Doses of Tofacitinib (CP-690,550) or Adalimumab in Subjects With Active Psoriatic Arthritis Study Centers: The study was conducted at 94 centers in Australia (5 centers), Belgium (2 centers), Bulgaria (5 centers), Canada (3 centers), Czech Republic (6 centers), France (1 center), Germany (6 centers), Hungary (4 centers), Mexico (6 centers), Poland (13 centers), Russian Federation (8 centers), Slovakia (4 centers), Spain (6 centers), Taiwan (4 centers), United Kingdom (5 centers), and United States (16 centers) (enrolled at least 1 subject); an additional 41 centers were shipped study drug, but did not enroll any subjects. Study Initiation Date and Primary Completion or Final Completion Dates: Study Initiation Date: 20 January 2014 Final Completion Date (Last Subject Last Visit): 18 December 2015 Phase of Development: Phase 3 Study Objectives: Primary Objectives 1. To compare the efficacy of tofacitinib at doses of 5 mg twice daily (BID) and 10 mg BID versus placebo for the treatment of rheumatological signs and symptoms of psoriatic arthritis (PsA), in subjects with active PsA who have had an inadequate response to a conventional synthetic (or non-biologic) disease-modifying anti-rheumatic drug (csDMARD). 2. To compare physical function status of subjects with active PsA who have had an inadequate response to a csDMARD after administration of tofacitinib at doses of 5 mg BID and 10 mg BID versus placebo. 3. To compare the safety and tolerability of 2 doses (5 mg BID and 10 mg BID) of tofacitinib versus placebo in subjects with active PsA who have had an inadequate response to a csDMARD. 1. To estimate the difference between tofacitinib and adalimumab at Month 12 in the mean change from Baseline (Δ) in modified Total Sharp Score (mTSS). 2. To estimate the difference in the rate of progressors (defined as ΔmTSS >0.5, an increase) between tofacitinib and adalimumab at Month 12. 3. To compare efficacy of tofacitinib at doses of 5 mg BID and 10 mg BID versus placebo on all health outcomes measures as appropriate for the specific outcome. 4. To compare the efficacy of tofacitinib at doses of 5 mg BID and 10 mg BID versus placebo for the treatment of dermatological signs and symptoms of PsA in subjects with active PsA. 5. To compare the efficacy of adalimumab 40 mg subcutaneously (SC) every (q) 2 weeks versus placebo for the treatment of rheumatologic and dermatologic signs and symptoms of PsA, in subjects with active PsA. 6. To compare physical function status of subjects with active PsA after administration of adalimumab 40 mg SC q 2 weeks versus placebo. 7. To estimate the durability of American College of Rheumatology Response Criteria 20% (ACR20), 50% (ACR50), 70% (ACR70), and Health Assessment Questionnaire - Disability Index (HAQ-DI). 8. To compare the efficacy of adalimumab 40 mg injected SC q 2 weeks versus placebo on all health outcome measures as appropriate for the specific outcome. 9. To estimate the efficacy of tofacitinib at doses of 5 mg BID and 10 mg BID versus adalimumab 40 mg SC q 2 weeks on signs and symptoms and physical function. 10. To estimate the safety and tolerability of 2 doses (5 mg BID and 10 mg BID) of tofacitinib versus adalimumab 40 mg SC q 2 weeks in subjects with active PsA. METHODS Study Design: This was a Phase 3 randomized, multicenter, 12-month, double-blind, double-dummy, placebo-controlled, parallel treatment group study in subjects with active PsA. A total of approximately 400 eligible subjects were planned to be randomized in a 2:2:2:1:1 ratio to 1 of the following 5 parallel treatment sequences (Figure 1). Abbreviations: ACR20 = American College of Rheumatology Response Criteria 20%; BID = twice daily; HAQ-DI = Health Assessment Questionnaire - Disability Index; SC = subcutaneous; Seq = sequence; q = every; wk = week. Primary Endpoints: ACR20, HAQ-DI were measured at Month 3 during the placebo-controlled period. At the Month 3 visit, subjects in Treatment Sequence D and E advanced to the second predetermined treatment in a blinded fashion for the remainder of the study. Eligible subjects remained on a stable dose of 1 csDMARD (ie, methotrexate, sulfasalazine, leflunomide, or others as approved by the Pfizer study clinician) as background therapy. At the end of Month 12, eligible subjects may have enrolled into the open-label, long-term extension Study A3921092. Number of Subjects (Planned and Analyzed): A total of 400 subjects were planned to be enrolled in this study (Table 1); 100 to tofacitinib 5 mg BID, 100 to tofacitinib 10 mg BID, 100 to adalimumab 40 mg SC q 2 weeks, 50 to placebotofacitinib 5 mg BID and 50 to placebotofacitinib 10 mg BID. A total of 422 subjects were randomized in this study; 107 to tofacitinib 5 mg BID, 104 to tofacitinib 10 mg BID, 106 to adalimumab 40 mg SC q 2 weeks, 52 to placebotofacitinib 5 mg BID and 53 to placebotofacitinib 10 mg BID. To be eligible for participation in this study, a subject must have met the ClASsification Criteria for Psoriatic ARthritis (CASPAR) criteria, having had inflammatory articular disease (joint, spine, or entheseal) with 3 points from the following 5 categories: a. Evidence of current psoriasis, a personal history of psoriasis, or a family history of psoriasis. Current psoriasis was defined as psoriatic skin or scalp disease present today as judged by a rheumatologist or dermatologist (current psoriasis was assigned a score of 2; all other features were assigned a score of 1). A personal history of psoriasis was defined as a history of psoriasis that may have been obtained from a subject, family physician, dermatologist, rheumatologist, or other qualified health care provider. A family history of psoriasis was defined as a history of psoriasis in a first- or second-degree relative according to subject report. b. Typical psoriatic nail dystrophy including onycholysis, pitting, and hyperkeratosis observed on current physical examination. c. A negative test result for the presence of rheumatoid factor by any method except latex but preferably by enzyme linked immunosorbent assay or nephelometry, according to the local laboratory reference range. d. Either current dactylitis, defined as swelling of an entire digit, or a history of dactylitis recorded by a rheumatologist. e. Radiographic evidence of juxtaarticular new bone formation, appearing as ill-defined ossification near joint margins (but excluding osteophyte formation) on plain radiographs of the hand or foot. The subject must have had active arthritis at both screening and Baseline, as defined by having both: 3 tender/painful joints on motion (out of 68 joints assessed) and 3 swollen joints (out of 66 joints assessed). The subject must have had active plaque psoriasis which had been diagnosed or confirmed by a dermatologist or a Sponsor-approved rheumatologist at screening only. All local standard of care practices for the administration of background csDMARD therapy, including laboratory testing, contraceptive requirements, follow-up care and contraindications were performed according to local standards of care throughout the study. Subjects must have received a permitted background csDMARD (ie, methotrexate, sulfasalazine, leflunomide, or others as approved by the Pfizer study clinician) dosed in accordance with the local regulatory label. Subjects remained on a stable dose of that csDMARD throughout the course of the study. Subjects had an inadequate response to at least 1 csDMARD due to lack of efficacy or toxicity/lack of toleration and must not have received any previous tumor necrosis factor inhibitor treatment. approved local label. Subjects who did not meet the New York Heart Association Class III and Class IV Congestive Heart Failure were eligible. Subjects with a history of hypersensitivity or infusion reactions to biologic agents were not eligible. Study Treatment: After a screening period, eligible subjects were randomized in a 2:2:2:1:1 ratio to Treatment Sequence A, Treatment Sequence B, Treatment Sequence C, Treatment Sequence D, or Treatment Sequence E (Table 1) via an automated randomization system (Interactive Voice Response System). The Sponsor provided tofacitinib as 5 mg tablets with corresponding matching placebo tablets. The blinded tofacitinib and its matched placebo assignment consisted of 1 active 5 mg tablet and 1 placebo tablet for the 5 mg dose sequence, 2 active 5 mg tablets for the 10 mg dose sequence, or 2 placebo tablets for the adalimumab and placebo sequences for the first 3 months of the treatment. Thereafter (Month 3 through Month 12), the blinded assignment consisted of 1 active 5 mg tablet and 1 placebo tablet for the 5 mg dose sequence, 2 active 5 mg tablets for the 10 mg dose sequence, 2 placebo tablets for the adalimumab treatment sequence, 1 active 5 mg tablet and 1 placebo tablet for the placebo × 3 months→tofacitinib 5 mg BID dose sequence, or 2 active 5 mg tablets for the placebo × 3 months→tofacitinib 10 mg BID dose sequence. The blinded active control study drug was provided by the Sponsor as adalimumab 40 mg prefilled syringes for the adalimumab treatment sequence and the corresponding matching placebo syringes for the other 4 treatment sequences. Table 1. Treatment Allocation Sequence Treatment Sequence Planned Number of Randomized Subjects A Tofacitinib 5 mg BID 100 B Tofacitinib 10 mg BID 100 C Adalimumab 40 mg SC q 2 weeks 100 D Placebo × 3 months tofacitinib 5 mg BID 50 E Placebo × 3 monthstofacitinib 10 mg BID 50 At the Month 3 visit, subjects in Treatment Sequences D and E advanced to the second predetermined treatment in a blinded fashion for the remainder of the study. Abbreviations: BID = twice daily; q = every; SC = subcutaneous The primary efficacy endpoints were:  ACR20 responder rates at Month 3 ACR20 response was calculated as a 20% improvement from Baseline in tender/painful and swollen joint counts and 20% improvement in 3 of the 5 remaining ACR-core set measures: patient and physician global assessments, pain, disability, and an acute-phase reactant. The specific components of the ACR assessments used in this study were: tender/painful joint count (68), swollen joint count (66), Patient’s Assessment of Arthritis Pain (Visual Analog Scale [VAS]), Patient’s Global Assessment of Arthritis (VAS), Physician’s Global Assessment of Arthritis (VAS), C-reactive protein (CRP), and HAQ-DI.  Change from Baseline () in HAQ-DI at Month 3 The HAQ-DI assesses the difficulty a participant has had in the past week in 8 domains of daily living activities: dressing and grooming, arising, eating, walking, hygiene, reach, grip, and other activities. Each activity category consists of 2 to 3 items. For each question, level of difficulty is scored from 0 to 3 with 0 = no difficulty, 1 = some difficulty, 2 = much difficulty, and 3 = unable to do. The score for each domain is the maximum (worst) score from the items/questions within the domain. A higher score indicates a greater disability. The secondary efficacy endpoints were:  Radiographic changes scored by modified Total Sharp Score (ΔmTSS) at Month 12 and progressor rates (defined as ΔmTSS >0.5, an increase) at Month 12 Radiographs of hands and feet were performed at Baseline and Month 12. All radiographs were scored by 2 independent, blinded assessors using a standardized, validated method using the van der Heijde Sharp score modified for PsA. For subjects who withdrew early, radiographs were obtained at the Early Termination Visit. The mTSS ranges from 0 to 528 with a higher score representing a worse disease status.  Signs and symptoms evaluated by:  ACR50 and ACR70 responder rates at all time points Similar to ACR20 response, ACR50 or ACR70 response was calculated as a 50% or 70% improvement from Baseline in ACR components.  ACR20 responder rates at all time points other than Month 3  HAQ-DI at all time points other than Month 3 The PsARC covers 4 measures: tender/painful joint count (68), swollen joint count (66), Physician’s Global Assessment of Arthritis (VAS), and Patient’s Global Assessment of Arthritis (VAS). The PsARC response is defined as improvement from Baseline in 2 of 4 items, 1 of which must be joint pain or swelling, without worsening in any measure. Improvement criteria: ≥20% improvement in Physician’s Global Assessment of Arthritis (VAS); ≥20% improvement in Patient’s Global Assessment of Arthritis (VAS); ≥30% improvement in tender/painful joint count (68); and ≥30% improvement in swollen joint count (66).  ΔPhysician’s Global Assessment of Psoriasis (PGA-PsO) response at Months 1, 3, 6, 9, and 12 The PGA-PsO is scored on a 5-point scale, reflecting a global consideration of the erythema, induration, and scaling across all psoriatic lesions. Average erythema, induration, and scaling are rated separately over the whole body according to a 5-point severity scale, scored as 0 = none; 1, 2, 3, or 4 = most severe. The severity rating scores are summed and the average taken; the total average is rounded to the nearest whole number score to determine the PGA-PsO.  Psoriasis Area and Severity Index 75 (PASI75) response at Months 1, 3, 6, 9, and 12 Psoriasis Area and Severity Index (PASI) determines psoriasis severity based on lesion severity and percentage of body surface area (BSA) affected. Lesion severity is assessed for erythema, induration and scaling; each evaluated separately for head and neck, upper limbs, trunk and lower limbs then rated for each body area on a 5 point scale: 0 = no involvement; 1 = slight; 2 = moderate; 3 = marked; 4 = very marked. BSA involvement is the extent (%) of body area affected by psoriasis and is given a numerical score: 0 = no involvement; 1 = 0 to 9%; 2 = 10 to 29%; 3 = 30 to 49%; 4 = 50 to 69%; 5 = 70 to 89%; 6 = 90 to 100%. In each area, the sum of the severity rating scores is multiplied by the score representing the percentage of this area involved by psoriasis, multiplied by a weighting factor (head 0.1; upper limbs 0.2; trunk 0.3; lower limbs 0.4). The sum of the numbers obtained for each of the 4 body areas is the PASI. PASI75 is defined as a ≥75% reduction from Baseline in PASI.  ΔDactylitis severity score (DSS) at Months 1, 3, 6, 9, and 12 Dactylitis is characterized by swelling of the entire finger or toe. The DSS is a function of finger circumference and tenderness, assessed and summed across all dactylitic digits. The severity of dactylitis is scored on a scale of 0 to 3, where 0 = no tenderness and 3 = extreme tenderness in each digit of the hands and feet. The range of total dactylitis scores for a patient is 0 to 60. A higher score indicates a greater degree of tenderness. Enthesitis Index and Leeds Enthesitis Index [LEI]) at Months 1, 3, 6, 9, and 12 Enthesitis is inflammation in the tendon, ligament, and joint capsule fiber insertion into bone. The LEI assesses enthesitis in 6 sites including (right and left): lateral epicondyle humerus, medial femoral condyle and Achilles tendon insertion. Tenderness is recorded as either present (1) or absent (0) for each of the 6 sites, for a total score of 0 to 6. Higher score indicates a greater number of sites affected by enthesitis. The SPARCC Enthesitis Index identifies the presence or absence of tenderness at 16 enthesial sites, including the bilateral Achilles tendons, plantar fascia insertion at the calcaneus, patellar tendon insertion at the base of the patella, quadriceps insertion into the superior border of the patella, supraspinatus insertion into the greater tuberosity of the humerus, and medial and lateral epicondyles. On examination, tenderness is recorded as present (1) or absent (0) for each of the 16 sites, with an overall total score ranging from 0 to 16. A higher score indicates a greater number of sites are affected by enthesitis.  Secondary Patient-Reported Outcomes of Physical Function and Health Outcome Measures (assessed at Months 1, 3, 6, 9, and 12):  ΔShort-Form-36 Health Survey Version 2 (SF-36v2), Acute (components and domains) The SF-36v2 acute is a 36-item measure that evaluates 8 domains: physical functioning, role-physical, bodily pain, general health, vitality, social functioning, role-emotional, and mental health. The health domains are aggregated into 2 summary scores known as the physical component summary score and the mental component summary score. The normalized scores were used in the analyses with higher scores representing better health-related quality of life.  ΔEuroQol-5 Dimension health state profile (EQ-5D) and Δ patient’s self-rated health on a vertical VAS recorded on the EQ-5D questionnaire (EQ-VAS) The EQ-5D is a descriptive system of health-related quality of life states consisting of 5 dimensions (mobility, self-care, usual activities, pain/discomfort, anxiety/depression) each of which can take 1 of 3 responses. The responses record 3 levels of severity (no problems/some or moderate problems/extreme problems) within a particular EQ-5D dimension. Standard vertical 0 to 100 mm VAS (similar to a thermometer) for recording an individual’s rating for their current health-related quality of life state. For EQ-VAS score, higher scores represent better health status; for the 5 domain scores, higher scores represent worse health status.  ΔFunctional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) (3 endpoints: total score, experience domain score and impact domain score) FACIT-F is a 13-item questionnaire, with each item score ranging from 0 to 4. Three calculated by summing the 13 items. FACIT-F experience domain score (range 0 to 20) is calculated by summing 5 items: I feel fatigued, I feel weak all over, I feel listless (“washed out”), I feel tired, and I have energy, while FACIT-F impact domain score (range 0 to 32) is calculated by summing the remaining 8 items. All responses are added with equal weight to obtain the total score. Higher scores represent better subject status (less fatigue).  Evaluation of spondylitis using ΔBath Anklyosing Spondylitis Disease Activity Index (BASDAI) BASDAI is a validated self-assessment tool used to determine disease activity in participants with ankylosing spondylitis. Utilizing a VAS of 0 to 10 (0 = none and 10 = very severe) participants answer 6 questions measuring discomfort, pain, and fatigue. The final BASDAI score averages the individual assessments for a final score ranging 0 to 10 cm. Higher scores represent more severe ankylosing spondylitis disease activity. Safety Evaluations: Incidence and severity of adverse events (AEs) were safety endpoints. A treatment-emergent adverse event (TEAE) was any event that had onset after the start of the first dose of study drug through the last subject visit, or onset prior to the first dose of study drug and worsened in severity after the first dose of study drug through the last subject visit. The TEAEs were reported as all-causality and treatment-related. The relationship to study drug was assessed by the Investigator. Statistical Methods: The Full Analysis Set (FAS) included all subjects who were randomized to the study and received at least 1 dose of the randomized study drug (tofacitinib, adalimumab or placebo) and was used for efficacy analyses. For analyses that used change from Baseline measurements, subjects must have Baseline value and at least one post-baseline value to be included in the FAS. The Safety Analysis Set included all subjects who received at least 1 dose of the study drug (tofacitinib, adalimumab or placebo). Subjects were excluded from the FAS for a specific endpoint if certain conditions were met for the endpoints as described in Table 2. Table 2. Endpoint Specific Analysis Sets Instrument/ Inclusion Rationale Endpoint PASI75 Subjects with Baseline PASI was not assessed if Baseline BSA <3% per the BSA ≥3% and Baseline study protocol; PASI = 0 means absence of psoriasis as PASI >0 measured by PASI. ∆PGA-PsO Subjects with Baseline PGA-PsO = 0 means no psoriasis disease at Baseline PGA-PsO >0 (skin was clear). ∆DSS Subjects with Baseline Baseline DSS = 0 means absence of dactylitis. Dactylitis DSS >0 was not an enrollment criterion so it was expected that only a subset of the subjects would have dactylitis at Baseline. ∆LEI Subjects with Baseline Baseline LEI score = 0 means absence of enthesitis as LEI >0 measured by LEI. Enthesitis was not an enrollment criterion so it was expected that only a subset of the subjects would have enthesitis at Baseline. ∆SPARCC Enthesitis Subjects with Baseline Baseline SPARCC Enthesitis Index score = 0 means Index SPARCC Enthesitis absence of enthesitis as measured by SPARCC. Index >0 Enthesitis was not an enrollment criterion so it was expected that only a subset of the subjects would have enthesitis at Baseline. ∆BASDAI Subjects with presence Absence of spondylitis at screening or Baseline BASDAI of spondylitis at score = 0 cm means absence of spondylitis. Spondylitis screening and Baseline was not an enrollment criterion so it was expected that BASDAI score >0 cm only a subset of the subjects would have spondylitis at Baseline. Abbreviations: ∆ = change from Baseline; BASDAI = Bath Ankylosing Spondylitis Disease Activity Index; BSA = body surface area; DSS = Dactylitis Severity Score; LEI = Leeds Enthesitis Index; PASI = Psoriasis Area and Severity Index; PGA-PsO = Physician’s Global Assessment of Psoriasis; PASI75 = a ≥75% reduction from Baseline in PASI; SPARCC = Spondyloarthritis Research Consortium of Canada. The primary efficacy analysis was conducted on data collected during the first 3 months where inferential comparisons to placebo entailed combining treatment sequences D and E to form 1 placebo group. The primary comparisons were between each tofacitinib dose and placebo at Month 3. For each comparison, the 2-sided 95% confidence interval (CI) and nominal p-value for the treatment difference are presented. No inferential treatment comparisons were made concerning the placebo sequence groups (ie, placebotofacitinib 5 mg or placebotofacitinib 10 mg BID) after Month 3. For binary endpoints such as ACR20 response, the normal approximation for the difference in binomial proportions was used to compare the treatment groups. Missing response was considered as non-response (MR=NR). Data for continuous endpoints collected at 2 or more post-Baseline visits were analyzed as ∆ with a Mixed Model for Repeated Measures (MMRM) without imputation for missing values. Two separate analyses were performed. The results for Week 2 (or Month 1) to Month 3 were generated using a MMRM including data from Week 2 (or Month 1) to Month 3 (combined placebo). The results for Month 4 (or Month 6) to Month 12 were Each analysis was based on a MMRM with the fixed effects of treatment, visit, treatment by visit interaction, geographic location and Baseline value; an unstructured covariance matrix was used. The Baseline was the value obtained on Day 1 pre-dose. The geographic locations were defined as: 1) United States and Canada, 2) Australia and Western Europe, 3) Russia and Eastern Europe, and 4) Rest of World. In order to protect the study-wise Type I error rate at the 0.05 (2-sided) level, a step-down approach was used, ie, each endpoint could only be tested if the prior endpoint’s p-value was ≤0.05. For the 2 primary endpoints at Month 3, the fixed sequence for testing against placebo was as follows: tofacitinib 10 mg ACR20 response rate, tofacitinib 5 mg ACR20 response rate, tofacitinib 10 mg ΔHAQ-DI and tofacitinib 5 mg ΔHAQ-DI. Upon achieving significance for the primary endpoints (4 tests), a step-down approach was also applied to a set of secondary efficacy endpoints including PASI75, ΔLEI, ΔDSS, Δphysical functioning domain of SF-36v2 and ΔFACIT-F scores (total, experience domain, and impact domain), comparing each tofacitinib dose vs placebo at Month 3. The order of testing was as listed above; for each endpoint, tofacitinib 10 mg was tested vs placebo first, followed by tofacitinib 5 mg vs placebo. Because the endpoints ACR50 and ACR70 can be viewed as extensions of the ACR20, and all belong to the ACR family of endpoints, a step-down approach to testing the ACR20, ACR50 and ACR70 at Month 3 was used for each endpoint and doses within each endpoint, ie, the high dose (10 mg BID) at a given endpoint could achieve significance only if the high dose at the prior endpoint was significant; the low dose (5 mg BID) at a given endpoint could achieve significance only if both the high dose at the same endpoint and the low dose at the prior endpoint was significant. Though this testing scheme did not protect the Type I error for the family of all possible comparisons, it provided Type I error protection for testing the family of ACR endpoints within each dose and doses within each ACR endpoint. In order to be more rigorous about establishing the onset of efficacy, a step-down approach with the ACR20 response from Month 3 to earlier time points (order of testing: Months 3, 2 and 1 and Week 2) was also used for each time point and doses within each time point, ie, the high dose (10 mg BID) at a given time point could achieve significance only if the high dose at the prior time point was significant; the low dose (5 mg BID) at a given time point could achieve significance only if both the high dose at the same time point and the low dose at the prior time point was significant. Though this testing scheme did not protect the Type I error for the family of all possible comparisons, it provided Type I error protection for testing the family of ACR20 time points within each dose and doses within each time point. Safety data were analyzed using descriptive statistics. Subject Disposition and Demography: Of the 611 subjects screened for entry into the study, 422 subjects were randomized to double-blind treatment; 107 subjects to tofacitinib 5 mg BID, 104 subjects to tofacitinib 10 mg BID, 106 subjects to adalimumab 40 mg SC q 2 weeks, 52 subjects to placebotofacitinib 5 mg BID, and 53 subjects to placebotofacitinib 10 mg BID (Table 3). Overall, 373 (88.4%) subjects completed the study and 49 (11.6%) subjects discontinued the study up to Month 12. A higher percentage of subjects in the placebo treatment sequences (15.4% placebotofacitinib 5 mg BID and 18.9% placebotofacitinib 10 mg BID) discontinued the study than the tofacitinib or adalimumab treatment sequences (10.3% tofacitinib 5 mg BID, 7.7% tofacitinib 10 mg BID, and 11.3% adalimumab 40 mg SC q 2 weeks) up to Month 12. The percentage of discontinuations was lowest for the tofacitinib 10 mg BID treatment sequence and comparable between tofacitinib 5 mg BID and adalimumab treatment sequences up to Month 12. Table 3. Subject Evaluation Groups by Treatment Sequence, Month 12 Tofacitinib Tofacitinib Adalimumab Placebo  Placebo  Total 5 mg BID 10 mg BID 40 mg SC Tofacitinib Tofacitinib Number (%) of q 2 Weeks 5 mg BID 10 mg BID Subjects Screened - 611 Assigned to 107 104 106 52 53 422 study drug Treated 107 (100.0) 104 (100.0) 106 (100.0) 52 (100.0) 53 (100.0) 422 (100.0) Completed 96 (89.7) 96 (92.3) 94 (88.7) 44 (84.6) 43 (81.1) 373 (88.4) Discontinued 11 (10.3) 8 (7.7) 12 (11.3) 8 (15.4) 10 (18.9) 49 (11.6) Analyzed for efficacy FAS 107 (100.0) 104 (100.0) 106 (100.0) 52 (100.0) 53 (100.0) 422 (100.0) Analyzed for safety Safety 107 (100.0) 104 (100.0) 106 (100.0) 52 (100.0) 53 (100.0) 422 (100.0) Analysis Set FAS – All subjects who were randomized to the study and received at least 1 dose of the randomized study drug (tofacitinib, adalimumab or placebo). Safety Analysis Set (Safety) – All subjects who received at least 1 dose of the study drug (tofacitinib, adalimumab or placebo). Percentages for the ‘treated’ row were calculated using the number of randomized subjects as the denominator. Other percentages were calculated using the number of treated subjects as the denominator. Abbreviations: AE = adverse event; BID = twice daily; FAS = Full Analysis Set; q = every; SC = subcutaneous. The most common reasons for discontinuation from the study by Month 12 included no longer willing to participate in the study and AEs considered related to study drug (9 [2.1%] subjects each). Table 4. Subject Discontinuation by Treatment Sequence, at Month 12 (Safety Analysis Set) Tofacitinib Tofacitinib Adalimumab Placebo  Placebo  Number (%) of Subjects 5 mg BID 10 mg BID 40 mg SC q 2 Tofacitinib Tofacitinib Total Weeks 5 mg BID 10 mg BID Subject died 0 0 0 1 (1.9) 0 1 (0.2) Relation to study drug not defineda 5 (4.7) 5 (4.8) 8 (7.5) 5 (9.6) 8 (15.1) 31 (7.3) Did not meet entrance criteria 1 (0.9) 0 1 (0.9) 0 0 2 (0.5) Insufficient clinical response 0 1 (1.0) 2 (1.9) 2 (3.8) 0 5 (1.2) Lost to follow-up 0 2 (1.9) 1 (0.9) 0 0 3 (0.7) No longer willing to participate in study 2 (1.9) 0 3 (2.8) 2 (3.8) 2 (3.8) 9 (2.1) Other 1 (0.9) 1 (1.0) 1 (0.9) 1 (1.9) 3 (5.7) 7 (1.7) Protocol violation 1 (0.9) 1 (1.0) 0 0 3 (5.7) 5 (1.2) Related to study drugb 2 (1.9) 2 (1.9) 2 (1.9) 2 (3.8) 1 (1.9) 9 (2.1) Adverse event 2 (1.9) 2 (1.9) 2 (1.9) 2 (3.8) 1 (1.9) 9 (2.1) Not related to study drugb 4 (3.7) 1 (1.0) 2 (1.9) 0 1 (1.9) 8 (1.9) Adverse event 4 (3.7) 1 (1.0) 2 (1.9) 0 1 (1.9) 8 (1.9) Total 11 (10.3) 8 (7.7) 12 (11.3) 8 (15.4) 10 (18.9) 49 (11.6) Discontinued status was determined from the subject summary page at the end of study. Abbreviations: AE = adverse event; BID = twice daily; CRF = Case Report Form; q = every; SC = subcutaneous. a. All assessments where the relation to study drug was not defined. b. Relationship was determined by Investigator’s assessment of relationship to study treatment on the AE CRF page. There were more female (225 [53.3%] subjects) than male (197 [46.7%] subjects) subjects. Mean age were similar across the treatment sequences with an overall mean age of 47.9 years. Table 5. Demographic and Baseline Characteristics by Treatment Sequence, Safety Analysis Set Number (%) Tofacitinib Tofacitinib Adalimumab Placebo  Placebo  Overall of Subjects 5 mg BID 10 mg BID 40 mg SC Tofacitinib Tofacitinib q 2 Weeks 5 mg BID 10 mg BID Total 107 104 106 52 53 422 Age (years)a Mean 49.4 46.9 47.4 46.1 49.3 47.9 SD 12.6 12.4 11.3 10.4 13.8 12.1 Range 20-72 18-74 23-81 22-72 19-74 18-81 18-44 36 (33.6) 42 (40.4) 42 (39.6) 25 (48.1) 19 (35.8) 164 (38.9) 45-64 59 (55.1) 54 (51.9) 57 (53.8) 25 (48.1) 25 (47.2) 220 (52.1) 65-74 12 (11.2) 8 (7.7) 6 (5.7) 2 (3.8) 9 (17.0) 37 (8.8) 75-84 0 0 1 (0.9) 0 0 1 (0.2) 85 0 0 0 0 0 0 Gender Female 57 (53.3) 62 (59.6) 50 (47.2) 24 (46.2) 28 (52.8) 225 (53.3) Male 50 (46.7) 42 (40.4) 56 (52.8) 28 (53.8) 25 (47.2) 197 (46.7) Categories of parameters were analyzed as number (%) of subjects in each category. There were no subjects <18 years old in the study. Abbreviations: BID = twice daily; q = every; SC = subcutaneous; SD = standard deviation. a. Age at screening. Efficacy Results: Primary Efficacy Endpoints ACR20 Response Rates at Month 3 The primary analysis of ACR20 response rates at Month 3 was conducted on the FAS with MR = NR using normal approximation for the difference in binomial proportions. The ACR20 response rate was statistically significantly higher (ie, superior) for both tofacitinib 5 mg BID and 10 mg BID dose treatment groups than the placebo treatment group at Month 3 (Table 6). The ACR20 response rate was higher for the adalimumab 40 mg SC q 2 weeks treatment group than placebo at Month 3 (2-sided 95% CI for the difference excluded 0). ΔHAQ-DI at Month 3 The primary analysis of ∆HAQ-DI data at Month 3 was conducted on the FAS without Month 3 (Table 7). The mean ∆HAQ-DI (decrease) was higher than placebo for the adalimumab 40 mg SC q 2 weeks treatment group at Month 3 (2-sided 95% CI for the difference excluded 0). Table 6. Normal Approximation to ACR20 Response Rates at Month 3 (FAS, Missing Response = Non-Response) – Treatment Comparisons – Primary Analysis Visit Treatment Group N n Response SE Difference (Active – Placebo) Rate (%) (%) Difference SE of 95% CI P-value (%) Difference (%) Lower (%) Upper (%) Month 3 Tofa 5 107 54 50.47 4.83 17.13 6.67 4.06 30.21 0.0102 Tofa 10 104 63 60.58 4.79 27.24 6.64 14.22 40.26 <0.0001 ADA 106 55 51.89 4.85 18.55 6.69 5.45 31.66 0.0055 PBO 105 35 33.33 4.60 ACR20 response was calculated as a 20% improvement from Baseline in tender/painful and swollen joint counts and 20% improvement from Baseline in 3 of the 5 remaining ACR-core set measures: Patient’s Assessment of Arthritis Pain (VAS), Patient’s Global Assessment of Arthritis (VAS), Physician’s Global Assessment of Arthritis (VAS), C-reactive protein, and HAQ-DI. Two-sided 95% CIs and p-values were based on the normal approximation for the difference in binomial proportions. P-values are nominal. Abbreviations: ACR20 = American College of Rheumatology Response Criteria 20%; ADA = adalimumab 40 mg SC q 2 weeks; BID = twice daily; CI = confidence interval; FAS = Full Analysis Set; HAQ-DI= Health Assessment Questionnaire - Disability Index; N = number of subjects in FAS; n = number of responders; PBO = placebo; q = every; SC = subcutaneous; SE = standard error; Tofa = tofacitinib; Tofa 5 = tofacitinib 5 mg BID; Tofa 10 = tofacitinib 10 mg BID; VAS=visual analog scale. Table 7. Statistical Analysis (Repeated Measures Model) of HAQ-DI at Month 3 (FAS, No Imputation) – Treatment Comparisons - Primary Analysis Visit Treatment Group N n LS Mean SE Difference (Active – Placebo) Difference SE of Difference 95% CI P-value Lower Upper Month 3 Tofa 5 107 103 -0.3499 0.04665 -0.1697 0.06173 -0.2910 -0.0483 0.0062 Tofa 10 104 103 -0.3998 0.04716 -0.2196 0.06184 -0.3411 -0.0980 0.0004 ADA 106 101 -0.3808 0.04767 -0.2005 0.06145 -0.3213 -0.0797 0.0012 PBO 104a 102 -0.1802 0.05031 Results were based on a MMRM with the fixed effects of treatment, visit, treatment by visit interaction, geographic location and Baseline value; an unstructured covariance matrix was used. P-values are nominal. Abbreviations: ∆ = change from Baseline; ADA = adalimumab 40 mg SC q 2 weeks; BID = twice daily; FAS = Full Analysis Set; HAQ-DI = Health Assessment Questionnaire - Disability Index; LS Mean = least squares mean; MMRM = Mixed Model for Repeated Measures; N = number of unique subjects in the longitudinal model; n = number of subjects evaluable at Month 3; PBO = placebo; q = every; SC = subcutaneous; SE = standard error; Tofa 5 = tofacitinib 5 mg BID; Tofa 10 = tofacitinib 10 mg BID. a. One placebo subject was excluded from the analysis (no post-Baseline assessments). ΔmTSS at Month 12 Mean ΔmTSS was comparable between each tofacitinib dose treatment sequence (5 mg BID and 10 mg BID) and adalimumab at Month 12 (Table 8). Table 8. ∆mTSS at Month 12 (FAS, Linear Extrapolation) Visit Treatment N LS Mean SE Month 12 Tofa 5 98 0.01 0.067 Tofa 10 99 -0.01 0.067 ADA 95 -0.07 0.069 PBO  Tofa 5 48 0.00 0.094 PBO  Tofa 10 45 0.09 0.099 In FAS, number of subjects in tofacitinib 5 mg BID: 107; tofacitinib 10 mg BID: 104; adalimumab 40 mg SC q 2 Weeks: 106; placebotofacitinib 5 mg BID: 52; placebotofacitinib 10 mg BID: 53. Results were based on an ANCOVA model with the fixed effects of treatment, geographic location and Baseline value as a covariate. The linearly extrapolated value at Month 12 was calculated as Y = B+([X – B]/[date of assessment - date of Baseline + 1]) × 337, where X was the value obtained prior to Month 12 and B was the Baseline value. Abbreviations: ∆ = change from Baseline; ADA = adalimumab 40 mg SC q 2 weeks; ANCOVA = analysis of covariance; BID = twice daily; FAS = Full Analysis Set; LS Mean = least squares mean; q = every; mTSS = modified Total Sharp Score; N = total number of subjects in ANCOVA analysis; PBO = placebo; SC = subcutaneous; SE = standard error; Tofa 5 = tofacitinib 5 mg BID; Tofa 10 = tofacitinib 10 mg BID. mTSS Progressor Rates at Month 12 The rates of progressors (defined as ∆mTSS >0.5, an increase) were low and were comparable between each tofacitinib dose treatment sequence (5 mg BID and 10 mg BID) and adalimumab at Month 12 (Table 9). Table 9. mTSS Progressor Rates (>0.5 Increase From Baseline in mTSS) at Month 12 (FAS, Linear Extrapolation) Visit Treatment N n Progressor Rate (%) SE Month 12 Tofa 5 98 4 4.08 2.00 Tofa 10 99 5 5.05 2.20 ADA 95 2 2.11 1.47 PBO  Tofa 5 48 2 4.17 2.88 PBO  Tofa 10 45 4 8.89 4.24 In FAS, number of subjects in tofacitinib 5 mg BID: 107; tofacitinib 10 mg BID: 104; adalimumab 40 mg SC q 2 Weeks: 106; placebotofacitinib 5 mg BID: 52; placebotofacitinib 10 mg BID: 53. Progressor was defined as a >0.5 increase from Baseline in mTSS. The linearly extrapolated value of mTSS at Month 12 was calculated as Y = B+([X – B]/[date of assessment - date of Baseline + 1]) × 337, where X was the value obtained prior to Month 12 and B was the Baseline value. Abbreviations: ADA = adalimumab 40 mg SC q 2 weeks; BID = twice daily; FAS = Full Analysis Set; mTSS = modified Total Sharp Score; N = number of subjects evaluable at Month 12 after linear extrapolation; n = number of progressors; PBO = placebo; q = every; SC = subcutaneous; SE = standard error; tofa 5 = tofacitinib 5 mg BID; tofa 10 = tofacitinib 10 mg BID. Early onset of efficacy in ACR20 response was shown with both tofacitinib doses (5 mg BID and 10 mg BID) as demonstrated by a statistically significant superior response to placebo at Week 2 (first post-Baseline assessment), Month 1, and Month 2 (Table 10). ACR20 response rates were maintained or improved in the active treatment sequences to Month 6 and Month 12 for tofacitinib 5 mg BID (58.88% and 68.22%, respectively) and tofacitinib 10 mg BID (67.31% and 70.19%, respectively), and adalimumab 40 mg SC q 2 weeks (64.15% and 60.38%, respectively); while response in the original placebo treatment sequences increased to Month 6 and Month 12 (59.62% and 67.31% for placebotofacitinib 5 mg BID and 56.60% and 58.49% for placebotofacitinib 10 mg BID) during the double-blind treatment period after Month 3 (Table 10). ACR20 response rates were similar for both tofacitinib dose treatment sequences (5 mg BID and 10 mg BID) at Month 12 (Table 10). Table 10. Normal Approximation to ACR20 Response Rates at Week 2 and Months 1, 2, 4, 6, and 12 (FAS, Missing Response = Non-Response) – Treatment Comparisons Visit Treatment N n Response SE (%) Difference (Active – Placebo) Rate (%) Difference SE of 95% CI P-value (%) Difference (%) Lower (%) Upper (%) Week 2 Tofa 5 107 24 22.43 4.03 16.72 4.63 7.65 25.78 0.0003 Tofa 10 104 33 31.73 4.56 26.02 5.10 16.03 36.00 <0.0001 ADA 106 23 21.70 4.00 15.98 4.60 6.97 25.00 0.0005 PBO 105 6 5.71 2.27 Month 1 Tofa 5 107 37 34.58 4.60 24.10 5.48 13.35 34.85 <0.0001 Tofa 10 104 50 48.08 4.90 37.60 5.74 26.35 48.85 <0.0001 ADA 106 30 28.30 4.38 17.83 5.30 7.44 28.21 0.0008 PBO 105 11 10.48 2.99 Month 2 Tofa 5 107 47 43.93 4.80 17.26 6.45 4.61 29.91 0.0075 Tofa 10 104 57 54.81 4.88 28.14 6.51 15.37 40.91 <0.0001 ADA 106 62 58.49 4.79 31.82 6.44 19.19 44.45 <0.0001 PBO 105 28 26.67 4.32 Month 4 Tofa 5 107 65 60.75 4.72 NR NR NR NR NR Tofa 10 104 60 57.69 4.84 NR NR NR NR NR ADA 106 61 57.55 4.80 NR NR NR NR NR PBO  Tofa 10 52 27 51.92 6.93 NR NR NR NR NR PBO  Tofa 10 53 28 52.83 6.86 NR NR NR NR NR Month 6 Tofa 5 107 63 58.88 4.76 NR NR NR NR NR Tofa 10 104 70 67.31 4.60 NR NR NR NR NR ADA 106 68 64.15 4.66 NR NR NR NR NR PBO  Tofa 5 52 31 59.62 6.80 NR NR NR NR NR PBO  Tofa 10 53 30 56.60 6.81 NR NR NR NR NR Month 12 Tofa 5 107 73 68.22 4.50 NR NR NR NR NR Tofa 10 104 73 70.19 4.49 NR NR NR NR NR ADA 106 64 60.38 4.75 NR NR NR NR NR PBO  Tofa 5 52 35 67.31 6.51 NR NR NR NR NR PBO  Tofa 10 53 31 58.49 6.77 NR NR NR NR NR ACR20 was calculated as a 20% improvement from Baseline in tender/painful and swollen joint counts and 20% improvement from Baseline in 3 of the 5 remaining ACR-core set measures: Patient’s Assessment of Arthritis Pain (VAS), Patient’s Global Assessment of Arthritis (VAS), Physician’s Global Assessment of Arthritis (VAS), C-reactive protein, and HAQ-DI. Two-sided 95% CIs and p-values were based on the normal approximation for the difference in binomial proportions. P-values are nominal. Table 10. Normal Approximation to ACR20 Response Rates at Week 2 and Months 1, 2, 4, 6, and 12 (FAS, Missing Response = Non-Response) – Treatment Comparisons Visit Treatment N n Response SE (%) Difference (Active – Placebo) Rate (%) Difference SE of 95% CI P-value (%) Difference (%) Lower (%) Upper (%) Abbreviations: ACR20 = American College of Rheumatology Response Criteria 20%; ADA = adalimumab 40 mg SC q 2 weeks; BID = twice daily; CI = confidence interval; FAS = Full Analysis Set; HAQ-DI= Health Assessment Questionnaire - Disability Index; N = number of subjects in FAS; n = number of responders; NR = not reported; PBO = placebo; q = every; SC = subcutaneous; SE = standard error; Tofa 5 = tofacitinib 5 mg BID; Tofa 10 = tofacitinib 10 mg BID; VAS=visual analog scale. ACR50 response rates were statistically significantly higher in active-treated arms than in the placebo arm at Month 3 during the double-blind placebo-controlled period. At Month 3, the ACR50 response rates were 28.04% for tofacitinib 5 mg BID, 40.38% for tofacitinib 10 mg BID, 33.02% for adalimumab 40 mg SC q 2 weeks, and 9.52% for placebo (Table 11). ACR50 response rates were maintained or improved in the active treatment sequences to Month 6 and Month 12 for tofacitinib 5 mg BID (38.32% and 44.86%, respectively) tofacitinib 10 mg BID (46.15% and 48.08%, respectively), and adalimumab 40 mg SC q 2 weeks (42.45% and 40.57%, respectively); while response in the original placebo treatment groups increased to Month 6 and Month 12 (32.69% and 40.38% for placebotofacitinib 5 mg BID and 26.42% and 35.85% for placebotofacitinib 10 mg BID) during the double-blind treatment period after Month 3 (Table 11). ACR50 response rates were similar for both tofacitinib dose treatment sequences (5 mg BID and 10 mg BID) at Month 12 (Table 11). Table 11. Normal Approximation to ACR50 Response Rates Up to Month 12 (FAS, Missing Response = Non-Response) – Treatment Comparisons Visit Treatment N n Response SE (%) Difference (Active – Placebo) Rate (%) Difference SE of 95% CI P-value (%) Difference (%) Lower (%) Upper (%) Week 2 Tofa 5 107 7 6.54 2.39 5.59 2.57 0.55 10.63 0.0297 Tofa 10 104 7 6.73 2.46 5.78 2.63 0.62 10.94 0.0282 ADA 106 5 4.72 2.06 3.76 2.27 -0.68 8.21 0.0968 PBO 105 1 0.95 0.95 Month 1 Tofa 5 107 13 12.15 3.16 7.39 3.78 -0.02 14.80 0.0507 Tofa 10 104 20 19.23 3.86 14.47 4.39 5.87 23.07 0.0010 ADA 106 12 11.32 3.08 6.56 3.71 -0.72 13.84 0.0774 PBO 105 5 4.76 2.08 Month 2 Tofa 5 107 23 21.50 3.97 13.88 4.74 4.58 23.17 0.0034 Tofa 10 104 34 32.69 4.60 25.07 5.28 14.73 35.42 <0.0001 ADA 106 24 22.64 4.06 15.02 4.82 5.58 24.47 0.0018 PBO 105 8 7.62 2.59 Month 3 Tofa 5 107 30 28.04 4.34 18.51 5.20 8.32 28.71 0.0004 Tofa 10 104 42 40.38 4.81 30.86 5.60 19.89 41.84 <0.0001 ADA 106 35 33.02 4.57 23.50 5.39 12.93 34.06 <0.0001 PBO 105 10 9.52 2.86 Month 4 Tofa 5 107 38 35.51 4.63 NR NR NR NR NR Tofa 10 104 39 37.50 4.75 NR NR NR NR NR ADA 106 34 32.08 4.53 NR NR NR NR NR PBO  Tofa 5 52 11 21.15 5.66 NR NR NR NR NR PBO  Tofa 10 53 17 32.08 6.41 NR NR NR NR NR Month 6 Tofa 5 107 41 38.32 4.70 NR NR NR NR NR Tofa 10 104 48 46.15 4.89 NR NR NR NR NR ADA 106 45 42.45 4.80 NR NR NR NR NR PBO  Tofa 5 52 17 32.69 6.51 NR NR NR NR NR PBO  Tofa 10 53 14 26.42 6.06 NR NR NR NR NR Month 9 Tofa 5 107 45 42.06 4.77 NR NR NR NR NR Tofa 10 104 48 46.15 4.89 NR NR NR NR NR ADA 106 49 46.23 4.84 NR NR NR NR NR PBO  Tofa 5 52 22 42.31 6.85 NR NR NR NR NR PBO  Tofa 10 53 23 43.40 6.81 NR NR NR NR NR Table 11. Normal Approximation to ACR50 Response Rates Up to Month 12 (FAS, Missing Response = Non-Response) – Treatment Comparisons Visit Treatment N n Response SE (%) Difference (Active – Placebo) Rate (%) Difference SE of 95% CI P-value (%) Difference (%) Lower (%) Upper (%) Month 12 Tofa 5 107 48 44.86 4.81 NR NR NR NR NR Tofa 10 104 50 48.08 4.90 NR NR NR NR NR ADA 106 43 40.57 4.77 NR NR NR NR NR PBO  Tofa 5 52 21 40.38 6.80 NR NR NR NR NR PBO  Tofa 10 53 19 35.85 6.59 NR NR NR NR NR ACR50 was calculated as a 50% improvement from Baseline in tender/painful and swollen joint counts and 50% improvement from Baseline in 3 of the 5 remaining ACR- core set measures: Patient’s Assessment of Arthritis Pain (VAS), Patient’s Global Assessment of Arthritis (VAS), Physician’s Global Assessment of Arthritis (VAS), C-reactive protein, and HAQ-DI. Two-sided 95% CIs and p-values were based on the normal approximation for the difference in binomial proportions. P-values are nominal. Abbreviations: ACR50 = American College of Rheumatology Response Criteria 50%; ADA = adalimumab 40 mg SC q 2 weeks; BID = twice daily; CI = confidence interval; FAS = Full Analysis Set; HAQ-DI= Health Assessment Questionnaire - Disability Index; N = number of subjects in FAS; n = number of responders; NR = not reported; PBO = placebo; q = every; SC = subcutaneous; SE = standard error; Tofa 5 = tofacitinib 5 mg BID; Tofa 10 = tofacitinib 10 mg BID; VAS=visual analog scale. ACR70 response rates were similar among active treatment groups prior to Month 3. ACR70 response rates were statistically significantly higher in active-treated arms than in the placebo arm at Month 3 during the double-blind placebo-controlled period. At Month 3, the ACR70 response rates were 16.82% for tofacitinib 5 mg BID, 14.42% for tofacitinib 10 mg BID, 18.87% for adalimumab 40 mg SC q 2 weeks, and 4.76% for placebo (Table 12). ACR70 response rates were maintained or improved in the active treatment sequences to Month 6 and Month 12 for tofacitinib 5 mg BID (17.76% and 23.36%, respectively) and tofacitinib 10 mg BID (31.73% and 30.77%, respectively), and adalimumab 40 mg SC q 2 weeks (30.19% and 29.25%, respectively); while response in the original placebo treatment groups increased to Month 6 and Month 12 (19.23% and 23.08% for placebotofacitinib 5 mg BID and 13.21% and 22.64% for placebotofacitinib 10 mg BID) during the double-blind active treatment period after Month 3 (Table 12). ACR70 response rates were similar for both tofacitinib dose treatment sequences (5 mg BID and 10 mg BID) at Month 12 (Table 12). Table 12. Normal Approximation to ACR70 Response Rates Up to Month 12 (FAS, Missing Response = Non-Response) – Treatment Comparisons Visit Treatment N n Response SE (%) Difference (Active – Placebo) Rate (%) Difference SE of 95% CI P-value (%) Difference Lower (%) Upper (%) (%) Week 2 Tofa 5 107 0 0.00 0.00 2.86 1.87 -0.81 6.53 0.1267 Tofa 10 104 3 2.88 1.64 0.93 1.32 -1.65 3.51 0.4800 ADA 106 1 0.94 0.94 2.87 1.87 -0.79 6.53 0.1247 PBO 105 0 0.00 0.00 Month 1 Tofa 5 107 5 4.67 2.04 3.72 2.25 -0.69 8.13 0.0982 Tofa 10 104 8 7.69 2.61 6.74 2.78 1.29 12.19 0.0153 ADA 106 4 3.77 1.85 2.82 2.08 -1.25 6.90 0.1749 PBO 105 1 0.95 0.95 Month 2 Tofa 5 107 10 9.35 2.81 7.44 3.11 1.34 13.54 0.0169 Tofa 10 104 14 13.46 3.35 11.56 3.60 4.50 18.62 0.0013 ADA 106 13 12.26 3.16 10.36 3.45 3.59 17.13 0.0027 PBO 105 2 1.90 1.33 Month 3 Tofa 5 107 18 16.82 3.62 12.06 4.17 3.89 20.24 0.0038 Tofa 10 104 15 14.42 3.45 9.66 4.02 1.78 17.55 0.0163 ADA 106 20 18.87 3.80 14.11 4.33 5.62 22.60 0.0011 PBO 105 5 4.76 2.08 Month 4 Tofa 5 107 24 22.43 4.03 NR NR NR NR NR Tofa 10 104 23 22.12 4.07 NR NR NR NR NR ADA 106 21 19.81 3.87 NR NR NR NR NR PBO  Tofa 5 52 7 13.46 4.73 NR NR NR NR NR PBO  Tofa 10 53 8 15.09 4.92 NR NR NR NR NR Month 6 Tofa 5 107 19 17.76 3.69 NR NR NR NR NR Tofa 10 104 33 31.73 4.56 NR NR NR NR NR ADA 106 32 30.19 4.46 NR NR NR NR NR PBO  Tofa 5 52 10 19.23 5.47 NR NR NR NR NR PBO  Tofa 10 53 7 13.21 4.65 NR NR NR NR NR Month 9 Tofa 5 107 21 19.63 3.84 NR NR NR NR NR Tofa 10 104 31 29.81 4.49 NR NR NR NR NR ADA 106 30 28.30 4.38 NR NR NR NR NR PBO  Tofa 5 52 15 28.85 6.28 NR NR NR NR NR PBO  Tofa 10 53 12 22.64 5.75 NR NR NR NR NR Table 12. Normal Approximation to ACR70 Response Rates Up to Month 12 (FAS, Missing Response = Non-Response) – Treatment Comparisons Visit Treatment N n Response SE (%) Difference (Active – Placebo) Rate (%) Difference SE of 95% CI P-value (%) Difference Lower (%) Upper (%) (%) Month 12 Tofa 5 107 25 23.36 4.09 NR NR NR NR NR Tofa 10 104 32 30.77 4.53 NR NR NR NR NR ADA 106 31 29.25 4.42 NR NR NR NR NR PBO  Tofa 5 52 12 23.08 5.84 NR NR NR NR NR PBO  Tofa 10 53 12 22.64 5.75 NR NR NR NR NR ACR70 was calculated as a 70% improvement from Baseline in tender/painful and swollen joint counts and 70% improvement from Baseline in 3 of the 5 remaining ACR-core set measures: Patient’s Assessment of Arthritis Pain (VAS), Patient’s Global Assessment of Arthritis (VAS), Physician’s Global Assessment of Arthritis (VAS), C-reactive protein, and HAQ-DI. Two-sided 95% CIs and p-values were based on the normal approximation for the difference in binomial proportions. P-values are nominal. Abbreviations: ACR70 = American College of Rheumatology Response Criteria 70%; ADA = adalimumab 40 mg SC q 2 weeks; BID = twice daily; CI = confidence interval; FAS = Full Analysis Set; HAQ-DI = Health Assessment Questionnaire - Disability Index; N = number of subjects in FAS; n = number of responders; NR = not reported; PBO = placebo; q = every; SC = subcutaneous; SE = standard error; Tofa 5 = tofacitinib 5 mg BID; Tofa 10 = tofacitinib 10 mg BID; VAS=visual analog scale. The ACR component, ∆HAQ-DI, continued to decrease beyond the 3-month, placebo-controlled period and appeared to plateau between 6 and 12 months. ∆HAQ-DI was similar at Month 12 for both tofacitinib dose treatment sequences (Table 13). Table 13. Statistical Analysis (Repeated Measures Model) of ∆HAQ-DI at Month Week 2, Months 1, 2, 4, 6 9 and 12 (FAS, No Imputation) – Treatment Comparisons Visit Treatment N n LS Mean SE Difference (Active – Placebo) Difference Difference 95% CI P-value (%) (%) Lower Lower Week 2 Tofa 5 107 106 -0.1842 0.04131 -0.1005 0.05365 -0.2060 0.0050 0.0618 Tofa 10 104 102 -0.2089 0.04208 -0.1252 0.05391 -0.2312 -0.0192 0.0207 ADA 106 103 -0.2129 0.04246 -0.1292 0.05340 -0.2342 -0.0242 0.0160 PBO 104 102 -0.0837 0.04549 Month 1 Tofa 5 107 105 -0.2048 0.04363 -0.0824 0.05717 -0.1948 0.0299 0.1500 Tofa 10 104 103 -0.2676 0.04426 -0.1452 0.05736 -0.2580 -0.0325 0.0117 ADA 106 104 -0.3028 0.04465 -0.1804 0.05682 -0.2921 -0.0687 0.0016 PBO 104 103 -0.1224 0.04755 Month 2 Tofa 5 107 104 -0.2713 0.04626 -0.1031 0.06118 -0.2233 0.0172 0.0928 Tofa 10 104 104 -0.4009 0.04678 -0.2327 0.06128 -0.3532 -0.1122 0.0002 ADA 106 104 -0.3736 0.04719 -0.2054 0.06082 -0.3249 -0.0858 0.0008 PBO 104 102 -0.1682 0.04998 Month 4 Tofa 5 107 102 -0.4231 0.04982 NR NR NR NR NR Tofa 10 104 100 -0.4407 0.05039 NR NR NR NR NR ADA 106 102 -0.3643 0.05069 NR NR NR NR NR PBO  Tofa 5 52 50 -0.2850 0.07075 NR NR NR NR NR PBO  Tofa 10 52 50 -0.3302 0.07128 NR NR NR NR NR Month 6 Tofa 5 107 100 -0.4471 0.05136 NR NR NR NR NR Tofa 10 104 100 -0.4611 0.05179 NR NR NR NR NR ADA 106 99 -0.4259 0.05227 NR NR NR NR NR PBO  Tofa 5 52 48 -0.3142 0.07315 NR NR NR NR NR PBO  Tofa 10 52 48 -0.3841 0.07369 NR NR NR NR NR Month 9 Tofa 5 107 99 -0.5119 0.05038 NR NR NR NR NR Tofa 10 104 96 -0.4847 0.05096 NR NR NR NR NR ADA 106 96 -0.4304 0.05143 NR NR NR NR NR PBO  Tofa 5 52 47 -0.3843 0.07185 NR NR NR NR NR PBO  Tofa 10 52 45 -0.4839 0.07276 NR NR NR NR NR Table 13. Statistical Analysis (Repeated Measures Model) of ∆HAQ-DI at Month Week 2, Months 1, 2, 4, 6 9 and 12 (FAS, No Imputation) – Treatment Comparisons Visit Treatment N n LS Mean SE Difference (Active – Placebo) Difference Difference 95% CI P-value (%) (%) Lower Lower Month 12 Tofa 5 107 96 -0.5391 0.05324 NR NR NR NR NR Tofa 10 104 96 -0.5104 0.05365 NR NR NR NR NR ADA 106 94 -0.4478 0.05426 NR NR NR NR NR PBO  Tofa 5 52 44 -0.4104 0.07646 NR NR NR NR NR PBO  Tofa 10 52 44 -0.4569 0.07704 NR NR NR NR NR Two separate analyses were performed. The results for Week 2 to Month 3 were generated using a MMRM including data from Week 2 to Month 3 (combined placebo). The results for Month 4 to Month 12 were generated using a MMRM including data from Week 2 to Month 12 (separate placebo treatment sequences; discarding the results for Week 2 to Month 3). Each analysis included the fixed effects of treatment, visit, treatment by visit interaction, geographic location and Baseline value; an unstructured covariance matrix was used. P-values are nominal. Abbreviations: ∆ = change from Baseline; ADA = adalimumab 40 mg SC q 2 weeks; BID = twice daily; CI = confidence interval; FAS = Full Analysis Set; HAQ-DI = Health Assessment Questionnaire - Disability Index; LS Mean = least squares mean; MMRM = Mixed Model for Repeated Measures; N = number of unique subjects in the longitudinal model; n = number of subjects evaluable at each visit; NR = not reported; PBO = placebo; q = every; SC = subcutaneous; SE = standard error; Tofa 5 = tofacitinib 5 mg BID; Tofa 10 = tofacitinib 10 mg BID. At Month 3, greater mean reduction from Baseline in the ACR component, CRP, was observed for both tofacitinib doses (5 mg BID and 10 mg BID) and adalimumab, compared to placebo (Table 14). ∆Patient’s Assessment of Arthritis Pain at Month 3 At Month 3, greater mean reduction from Baseline in the ACR component, Patient’s Assessment of Arthritic Pain, was observed for both tofacitinib doses (5 mg BID and 10 mg BID) and adalimumab, compared to placebo (Table 14). ∆Patient’s Global Assessment of Arthritis at Month 3 At Month 3, greater mean reduction from Baseline in the ACR component, Patient’s Global Assessment of Arthritis, was observed for both tofacitinib doses (5 mg BID and 10 mg BID) and adalimumab, compared to placebo (Table 14). ∆Physician’s Global Assessment of Arthritis at Month 3 At Month 3, greater mean reduction from Baseline in the ACR component, Physician’s Global Assessment of Arthritis, was observed for tofacitinib 10 mg BID and adalimumab, compared to placebo. A numerically higher mean reduction from Baseline in Physician’s Global Assessment of Arthritis was observed for tofacitinib 5 mg BID compared to placebo (Table 14). ∆Tender/Painful Joint Count at Month 3 At Month 3, there was a greater mean reduction from Baseline in the ACR component, tender/painful joint count, for tofacitinib 10 mg BID over placebo. A numerically higher mean reduction from Baseline in tender/painful joint count was observed for tofacitinib 5 mg BID and adalimumab, compared to placebo (Table 14). ∆Swollen Joint Count at Month 3 At Month 3, greater mean reductions from Baseline in the ACR component, swollen joint count, were observed for both tofacitinib doses (5 mg BID and 10 mg BID) and adalimumab, compared to placebo (Table 14). Table 14. Statistical Analysis (Repeated Measures Model) of ΔACR Response Criteria Components (Except HAQ-DI) at Months 3 (FAS, No Imputation) – Treatment Comparisons Treatment N n LS Mean SE Difference (Active – Placebo) Difference SE of 95% CI P-value Difference Lower Upper ∆CRP (mg/L) Tofa 5 107 101 -5.5981 0.80656 -4.7338 1.07016 -6.8375 -2.6301 <0.0001 Tofa 10 104 103 -6.6004 0.80822 -5.7361 1.06717 -7.8339 -3.6382 <0.0001 ADA 106 99 -7.8955 0.82547 -7.0312 1.07129 -9.1371 -4.9253 <0.0001 PBO 104 101 -0.8643 0.86304 ∆Patient’s Assessment of Tofa 5 107 103 -21.49 2.325 -11.27 3.082 -17.32 -5.21 0.0003 Arthritis Pain (mm) Tofa 10 104 103 -27.10 2.342 -16.88 3.084 -22.94 -10.82 <0.0001 ADA 105 100 -21.87 2.389 -11.65 3.074 -17.69 -5.61 0.0002 PBO 104 102 -10.22 2.499 ∆Patient’s Global Tofa 5 107 103 -20.08 2.275 -8.67 3.022 -14.61 -2.73 0.0043 Assessment of Arthritis (mm) Tofa 10 104 103 -25.50 2.291 -14.09 3.025 -20.04 -8.15 <0.0001 ADA 106 101 -21.47 2.328 -10.06 3.014 -15.99 -4.14 0.0009 PBO 104 102 -11.40 2.439 ∆Physician’s Global Tofa 5 107 103 -27.44 1.998 -5.18 2.697 -10.48 0.12 0.0555 Assessment of Arthritis (mm) Tofa 10 103 101 -33.74 2.021 -11.48 2.709 -16.80 -6.15 <0.0001 ADA 106 101 -29.02 2.043 -6.76 2.694 -12.05 -1.46 0.0125 PBO 104 102 -22.26 2.121 ∆Tender/Painful Joint Tofa 5 107 103 -8.7 1.04 -1.9 1.41 -4.6 0.9 0.1855 Count (Joints) Tofa 10 104 103 -11.0 1.05 -4.1 1.41 -6.9 -1.3 0.0039 ADA 106 101 -7.6 1.07 -0.7 1.41 -3.5 2.0 0.5964 PBO 104 102 -6.9 1.10 ∆Swollen Joint Count Tofa 5 107 103 -6.5 0.58 -1.7 0.78 -3.3 -0.2 0.0265 (Joints) Tofa 10 104 103 -7.6 0.58 -2.8 0.78 -4.3 -1.2 0.0004 ADA 106 101 -6.5 0.59 -1.8 0.78 -3.3 -0.2 0.0261 PBO 104 102 -4.8 0.62 Table 14. Statistical Analysis (Repeated Measures Model) of ΔACR Response Criteria Components (Except HAQ-DI) at Months 3 (FAS, No Imputation) – Treatment Comparisons Treatment N n LS Mean SE Difference (Active – Placebo) Difference SE of 95% CI P-value Difference Lower Upper For each endpoint, the results for Month 3 were generated using a MMRM including data from Week 2 to Month 3 (combined placebo). The analysis was based on a MMRM with the fixed effects of treatment, visit, treatment by visit interaction, geographic location and Baseline value; an unstructured covariance matrix was used. P-values are nominal. Abbreviations: ∆ = change from Baseline; ADA = adalimumab 40 mg SC q 2 weeks; BID = twice daily; CI = confidence interval; CRP = C-reactive protein; FAS = Full Analysis Set; LS Mean = least squares mean; MMRM = Mixed Model for Repeated Measures; N = total number of unique subjects in the longitudinal model; n = number of subjects evaluable at each visit; NR = not reported; PBO = placebo; q = every; SC = subcutaneous; SE = standard error; Tofa 5 = tofacitinib 5 mg BID; Tofa 10 = tofacitinib 10 mg BID. PsARC response rates were higher in the tofacitinib 10 mg BID and adalimumab 40 mg SC q 2 weeks arms than in the placebo arm at Month 3 during the double-blind placebo-controlled period. At Month 3, the PsARC response rates were 51.40% for tofacitinib 5 mg BID, 70.19% for tofacitinib 10 mg BID, 61.32% for adalimumab 40 mg SC q 2 weeks, and 44.76% for placebo (Table 15). PsARC response rates were maintained or improved in the active treatment sequences to Month 6 and Month 12 for tofacitinib 5 mg BID (57.01% and 64.49%, respectively) and tofacitinib 10 mg BID (72.12% and 73.08%, respectively), and adalimumab 40 mg SC q 2 weeks (66.98% and 65.09%, respectively), while response rates in the original placebo treatment sequences increased to Month 6 and Month 12 (67.31% and 75.00% for placebotofacitinib 5 mg BID and 66.04% and 62.26% for placebotofacitinib 10 mg BID) during the double-blind treatment period after Month 3 (Table 15). Table 15. Normal Approximation to PsARC Response Rates Up to Month 12 (FAS, Missing Response = Non-Response) – Treatment Comparisons Visit Treatment N n Response SE (%) Difference (Active – Placebo) Rate (%) Difference SE of 95% CI P-value (%) Difference Lower (%) Upper (%) (%) Week 2 Tofa 5 107 34 31.78 4.50 22.25 5.34 11.79 32.71 <0.0001 Tofa 10 104 42 40.38 4.81 30.86 5.60 19.89 41.84 <0.0001 ADA 106 23 21.70 4.00 12.17 4.92 2.53 21.82 0.0134 PBO 105 10 9.52 2.86 Month 1 Tofa 5 107 45 42.06 4.77 20.15 6.25 7.90 32.40 0.0013 Tofa 10 104 51 49.04 4.90 27.13 6.35 14.69 39.58 <0.0001 ADA 106 43 40.57 4.77 18.66 6.25 6.42 30.91 0.0028 PBO 105 23 21.90 4.04 Month 2 Tofa 5 107 54 50.47 4.83 16.18 6.69 3.06 29.30 0.0156 Tofa 10 104 69 66.35 4.63 32.06 6.55 19.22 44.90 <0.0001 ADA 106 62 58.49 4.79 24.20 6.66 11.15 37.26 0.0003 PBO 105 36 34.29 4.63 Month 3 Tofa 5 107 55 51.40 4.83 6.64 6.85 -6.78 20.06 0.3322 Tofa 10 104 73 70.19 4.49 25.43 6.61 12.48 38.38 0.0001 ADA 106 65 61.32 4.73 16.56 6.78 3.28 29.84 0.0145 PBO 105 47 44.76 4.85 Month 4 Tofa 5 107 68 63.55 4.65 NR NR NR NR NR Tofa 10 104 68 65.38 4.67 NR NR NR NR NR ADA 106 71 66.98 4.57 NR NR NR NR NR PBO  Tofa 5 52 32 61.54 6.75 NR NR NR NR NR PBO  Tofa 10 53 30 56.60 6.81 NR NR NR NR NR Month 6 Tofa 5 107 61 57.01 4.79 NR NR NR NR NR Tofa 10 104 75 72.12 4.40 NR NR NR NR NR ADA 106 71 66.98 4.57 NR NR NR NR NR PBO  Tofa 5 52 35 67.31 6.51 NR NR NR NR NR PBO  Tofa 10 53 35 66.04 6.51 NR NR NR NR NR Month 9 Tofa 5 107 75 70.09 4.43 NR NR NR NR NR Tofa 10 104 73 70.19 4.49 NR NR NR NR NR ADA 106 71 66.98 4.57 NR NR NR NR NR PBO  Tofa 5 52 36 69.23 6.40 NR NR NR NR NR PBO  Tofa 10 53 37 69.81 6.31 NR NR NR NR NR Table 15. Normal Approximation to PsARC Response Rates Up to Month 12 (FAS, Missing Response = Non-Response) – Treatment Comparisons Visit Treatment N n Response SE (%) Difference (Active – Placebo) Rate (%) Difference SE of 95% CI P-value (%) Difference Lower (%) Upper (%) (%) Month 12 Tofa 5 107 69 64.49 4.63 NR NR NR NR NR Tofa 10 104 76 73.08 4.35 NR NR NR NR NR ADA 106 69 65.09 4.63 NR NR NR NR NR PBO  Tofa 5 52 39 75.00 6.00 NR NR NR NR NR PBO  Tofa 10 53 33 62.26 6.66 NR NR NR NR NR Two-sided 95% CI and p-value were based on the normal approximation for the difference in binomial proportions. P-values are nominal. Abbreviations: ADA = adalimumab 40 mg SC q 2 weeks; BID = twice daily; CI = confidence interval; FAS = Full Analysis Set; N = number of subjects in FAS; n = number of responders; NR = not reported; PBO = placebo; PsARC = Psoriatic Arthritis Response Criteria; q = every; SC = subcutaneous; SE = standard error; Tofa 5 = tofacitinib 5 mg BID; Tofa 10 = tofacitinib 10 mg BID. For subjects with a Baseline PGA-PsO score >0, the mean reductions from Baseline in PGA-PsO response of both tofacitinib doses (5 mg BID and 10 mg BID) and adalimumab were greater than placebo at Month 3 during the double-blind placebo-controlled period. At Month 3, the LS mean reductions were -1.0 for tofacitinib 5 mg BID, -1.2 for tofacitinib 10 mg BID, -1.0 for adalimumab 40 mg SC q 2 weeks, and -0.4 for placebo (Table 16). The mean reductions from Baseline in PGA-PsO response were maintained or improved in the active treatment sequences to Month 6 and Month 12 for tofacitinib 5 mg BID and tofacitinib 10 mg BID, and adalimumab 40 mg SC q 2 weeks, while response in the original placebo treatment sequences increased to Month 6 and Month 12 during the double-blind treatment period after Month 3 (Table 16). Table 16. Statistical Analysis (Repeated Measures Model) of ∆PGA-PsO at Months 1, 3, 6, 9, and 12 (for Subjects With Baseline PGA-PsO >0 in FAS, No Imputation) – Treatment Comparisons Visit Treatment N n LS Mean SE Difference (Active – Placebo) Difference SE of 95% CI P-value Difference Lower Upper Month 1 Tofa 5 101 100 -0.7 0.07 -0.4 0.10 -0.6 -0.2 <0.0001 Tofa 10 98 96 -0.8 0.08 -0.5 0.10 -0.7 -0.3 <0.0001 ADA 102 100 -0.5 0.08 -0.2 0.10 -0.4 -0.1 0.0094 PBO 100 99 -0.2 0.08 Month 3 Tofa 5 101 98 -1.0 0.08 -0.6 0.11 -0.8 -0.3 <0.0001 Tofa 10 98 97 -1.2 0.08 -0.7 0.11 -1.0 -0.5 <0.0001 ADA 102 98 -1.0 0.09 -0.5 0.11 -0.7 -0.3 <0.0001 PBO 100 98 -0.4 0.09 Month 6 Tofa 5 101 96 -0.9 0.09 NR NR NR NR NR Tofa 10 98 94 -1.3 0.09 NR NR NR NR NR ADA 102 96 -1.2 0.09 NR NR NR NR NR PBO  Tofa 5 50 46 -0.7 0.12 NR NR NR NR NR PBO  Tofa 10 50 46 -0.9 0.13 NR NR NR NR NR Month 9 Tofa 5 101 95 -1.0 0.09 NR NR NR NR NR Tofa 10 98 91 -1.5 0.09 NR NR NR NR NR ADA 102 94 -1.2 0.09 NR NR NR NR NR PBO  Tofa 5 50 45 -0.7 0.12 NR NR NR NR NR PBO  Tofa 10 50 44 -1.3 0.13 NR NR NR NR NR Month 12 Tofa 5 101 91 -1.2 0.09 NR NR NR NR NR Tofa 10 98 90 -1.5 0.09 NR NR NR NR NR ADA 102 92 -1.2 0.09 NR NR NR NR NR PBO  Tofa 5 50 41 -0.9 0.13 NR NR NR NR NR PBO  Tofa 10 50 43 -1.3 0.13 NR NR NR NR NR Subjects with Baseline PGA-PsO = 0 were excluded from the analysis. Number of subjects in FAS with Baseline PGA-PsO>0 for tofacitinib 5 mg BID: 102; tofacitinib 10 mg BID: 98; adalimumab 40 mg SC q 2 weeks: 102; placebo: 101; placebotofacitinib 5 mg BID: 50; placebotofacitinib 10 mg BID: 51. Two separate analyses were performed. The results for Month 1 and Month 3 were generated using a MMRM including data from Month 1 to Month 3 (combined placebo). The results for Month 6 to Month 12 were generated using a MMRM including data from Month 1 to Month 12 (separate placebo treatment sequences; discarding the results for Month 1 to Month 3). Each model included the fixed effects of treatment, visit, treatment by visit interaction, geographic location and Baseline value; an unstructured covariance matrix was used. P-values are nominal. Table 16. Statistical Analysis (Repeated Measures Model) of ∆PGA-PsO at Months 1, 3, 6, 9, and 12 (for Subjects With Baseline PGA-PsO >0 in FAS, No Imputation) – Treatment Comparisons Visit Treatment N n LS Mean SE Difference (Active – Placebo) Difference SE of 95% CI P-value Difference Lower Upper Abbreviations: ∆ = change from Baseline; ADA = adalimumab 40 mg SC q 2 weeks; BID = twice daily; CI = confidence interval; FAS = Full Analysis Set; LS Mean = least squares mean; MMRM = Mixed Model for Repeated Measures; N = total number of unique subjects in the longitudinal model; n = number of subjects evaluable at each visit; NR = not reported; PBO = placebo; PGA-PsO = Physician’s Global Assessment of Psoriasis; q = every; SC = subcutaneous; SE = standard error; Tofa 5 = tofacitinib 5 mg BID; Tofa 10 = tofacitinib 10 mg BID. For subjects with Baseline BSA 3% and Baseline PASI >0, PASI75 response rates were statistically significantly higher in both tofacitinib dose treatment groups (5 mg BID and 10 mg BID) and adalimumab treatment group than in the placebo treatment group at Month 3 during the double-blind placebo-controlled period. PASI75 response rates continued to increase beyond the 3-month, placebo-controlled period and appeared to plateau between 6 and 12 months. PASI75 response rate for both tofacitinib dose treatment sequences appeared similar at Month 12 (Table 17). Table 17. Normal Approximation to PASI75 Response Rates at Months 1, 3, 6, 9, and 12 (for Subjects With Baseline BSA 3% and Baseline PASI >0 in FAS, Missing Response = Non-Response) – Treatment Comparisons Visit Treatment N n Response SE (%) Difference (Active – Placebo) Rate (%) Difference SE of 95% CI P-value (%) Difference Lower (%) Upper (%) (%) Month 1 Tofa 5 82 19 23.17 4.66 18.29 5.23 8.04 28.55 0.0005 Tofa 10 70 19 27.14 5.32 22.26 5.82 10.85 33.68 0.0001 ADA 77 11 14.29 3.99 9.41 4.64 0.31 18.51 0.0428 PBO 82 4 4.88 2.38 Month 3 Tofa 5 82 35 42.68 5.46 28.05 6.71 14.89 41.21 <0.0001 Tofa 10 70 31 44.29 5.94 29.65 7.11 15.73 43.58 <0.0001 ADA 77 30 38.96 5.56 24.33 6.79 11.02 37.64 0.0003 PBO 82 12 14.63 3.90 Month 6 Tofa 5 82 38 46.34 5.51 NR NR NR NR NR Tofa 10 70 42 60.00 5.86 NR NR NR NR NR ADA 77 42 54.55 5.67 NR NR NR NR NR PBO  Tofa 5 42 12 28.57 6.97 NR NR NR NR NR PBO  Tofa 10 40 17 42.50 7.82 NR NR NR NR NR Month 9 Tofa 5 82 36 43.90 5.48 NR NR NR NR NR Tofa 10 70 48 68.57 5.55 NR NR NR NR NR ADA 77 45 58.44 5.62 NR NR NR NR NR PBO  Tofa 5 42 14 33.33 7.27 NR NR NR NR NR PBO  Tofa 10 40 20 50.00 7.91 NR NR NR NR NR Month 12 Tofa 5 82 46 56.10 5.48 NR NR NR NR NR Tofa 10 70 47 67.14 5.61 NR NR NR NR NR ADA 77 43 55.84 5.66 NR NR NR NR NR PBO  Tofa 5 42 15 35.71 7.39 NR NR NR NR NR PBO  Tofa 10 40 21 52.50 7.90 NR NR NR NR NR PASI75 was defined as a 75% reduction from Baseline in PASI. Only subjects with Baseline BSA affected 3% (per study protocol) and Baseline PASI >0 are considered. Two-sided 95% CIs and p-values were based on the normal approximation for the difference in binomial proportions. P-values are nominal. Abbreviations: ∆ = change from Baseline; ADA = adalimumab 40 mg SC q 2 weeks; BID = twice daily; BSA = body surface area; CI = confidence interval; FAS = Full Analysis Set; N = number of subjects in FAS with Baseline BSA 3% and Baseline PASI >0; n = number of responders; NR = not reported; PASI75 = Psoriasis Area and Severity Index 75; PBO = placebo; q = every; SC = subcutaneous; SE = standard error; Tofa 5 = tofacitinib 5 mg BID; Tofa 10 = tofacitinib 10 mg BID. For subjects with Baseline DSS>0, at Month 3, greater mean reduction from Baseline in DSS was observed for tofacitinib 10 mg BID, but not tofacitinib 5 mg BID or adalimumab, compared to placebo. ΔDSS continued to decrease beyond the 3-month, placebo-controlled period and appeared to plateau between 6 and 12 months. ΔDSS for both tofacitinib dose treatment sequences appeared similar at Month 12 (Table 18). Table 18. Statistical Analysis (Repeated Measures Model) of ∆DSS at Months 1, 3, 6, 9, and 12 (for Subjects With Baseline DSS >0 in FAS, No Imputation) – Treatment Comparisons Visit Treatment N n LS Mean SE Difference (Active – Placebo) Difference SE of 95% CI P-value Difference Lower Upper Month 1 Tofa 5 60 58 -1.8 0.91 -2.4 1.15 -4.7 -0.1 0.0376 Tofa 10 60 59 -3.1 0.87 -3.6 1.16 -5.9 -1.3 0.0020 ADA 58 56 -2.1 0.93 -2.7 1.16 -4.9 -0.4 0.0219 PBO 57 56 0.6 1.02 Month 3 Tofa 5 60 58 -3.5 0.95 -1.5 1.22 -3.9 0.9 0.2270 Tofa 10 60 60 -5.5 0.91 -3.5 1.22 -5.9 -1.1 0.0044 ADA 58 56 -4.0 0.97 -2.0 1.23 -4.4 0.4 0.1040 PBO 57 55 -2.0 1.06 Month 6 Tofa 5 60 58 -5.2 1.01 NR NR NR NR NR Tofa 10 60 59 -6.4 0.99 NR NR NR NR NR ADA 58 55 -5.4 1.03 NR NR NR NR NR PBO  Tofa 5 29 28 -5.9 1.45 NR NR NR NR NR PBO  Tofa 10 28 25 -5.2 1.50 NR NR NR NR NR Month 9 Tofa 5 60 57 -7.0 0.60 NR NR NR NR NR Tofa 10 60 59 -7.2 0.58 NR NR NR NR NR ADA 58 53 -6.5 0.63 NR NR NR NR NR PBO  Tofa 5 29 27 -5.3 0.87 NR NR NR NR NR PBO  Tofa 10 28 25 -7.9 0.89 NR NR NR NR NR Month 12 Tofa 5 60 54 -7.4 0.65 NR NR NR NR NR Tofa 10 60 58 -7.5 0.62 NR NR NR NR NR ADA 58 52 -6.1 0.67 NR NR NR NR NR PBO  Tofa 5 29 26 -6.7 0.93 NR NR NR NR NR PBO  Tofa 10 28 24 -7.7 0.96 NR NR NR NR NR Subjects with Baseline Dactylitis Severity Score = 0 were excluded from the analysis. Number of subjects in FAS with Baseline Dactylitis Severity Score >0 for tofacitinib 5 mg BID: 61; tofacitinib 10 mg BID: 60; adalimumab 40 mg SC q 2 weeks: 58; placebo: 58; placebotofacitinib 5 mg BID: 29; placebotofacitinib 10 mg BID: 29. Two separate analyses were performed. The results for Month 1 and Month 3 were generated using a MMRM including data from Month 1 to Month 3 (combined placebo). The results for Month 6 to Month 12 were generated using a MMRM including data from Month 1 to Month 12 (separate placebo treatment sequences; discarding the results for Month 1 to Month 3). Each model included the fixed effects of treatment, visit, treatment by visit interaction, geographic location and Baseline value; an unstructured covariance matrix was used. P-values are nominal. Table 18. Statistical Analysis (Repeated Measures Model) of ∆DSS at Months 1, 3, 6, 9, and 12 (for Subjects With Baseline DSS >0 in FAS, No Imputation) – Treatment Comparisons Visit Treatment N n LS Mean SE Difference (Active – Placebo) Difference SE of 95% CI P-value Difference Lower Upper Abbreviations: ∆ = change from Baseline; ADA = adalimumab 40 mg SC q 2 weeks; BID = twice daily; CI = confidence interval; DSS = Dactylitis Severity Score; FAS = Full Analysis Set; LS Mean = least squares mean; MMRM = Mixed Model for Repeated Measures; N = total number of unique subjects in the longitudinal model; n = number of subjects evaluable at each visit; NR = not reported; PBO = placebo; q = every; SC = subcutaneous; SE = standard error; Tofa 5 = tofacitinib 5 mg BID; Tofa 10 = tofacitinib 10 mg BID. For subjects with Baseline LEI>0, at Month 3, tofacitinib 10 mg BID was statistically significantly superior to placebo (greater mean reduction from Baseline in LEI), but tofacitinib 5 mg BID was not superior to placebo. ΔLEI continued to decrease beyond the 3-month, placebo-controlled period and appeared to plateau between 6 and 12 months. ΔLEI for both tofacitinib dose treatment sequences appeared similar at Month 12 (Table 19). Table 19. Statistical Analysis (Repeated Measures Model) of ∆LEI at Months 1, 3, 6, 9, and 12 (for Subjects With Baseline LEI Score >0 in FAS, No Imputation) – Treatment Comparisons Visit Treatment N n LS Mean SE Difference (Active – Placebo) Difference SE of 95% CI P-value Difference Lower Upper Month 1 Tofa 5 74 74 -0.41 0.192 -0.15 0.231 -0.61 0.30 0.5108 Tofa 10 64 63 -0.57 0.213 -0.31 0.238 -0.78 0.15 0.1887 ADA 76 75 -0.42 0.203 -0.17 0.229 -0.62 0.28 0.4647 PBO 65 65 -0.26 0.219 Month 3 Tofa 5 74 70 -0.82 0.221 -0.39 0.279 -0.94 0.16 0.1670 Tofa 10 64 63 -1.46 0.240 -1.02 0.285 -1.59 -0.46 0.0004 ADA 76 73 -1.10 0.228 -0.66 0.276 -1.21 -0.12 0.0167 PBO 65 63 -0.43 0.246 Month 6 Tofa 5 74 72 -1.3 0.21 NR NR NR NR NR Tofa 10 64 61 -1.2 0.23 NR NR NR NR NR ADA 76 71 -1.3 0.22 NR NR NR NR NR PBO  Tofa 5 31 27 -1.0 0.32 NR NR NR NR NR PBO  Tofa 10 34 31 -1.3 0.30 NR NR NR NR NR Month 9 Tofa 5 74 70 -1.4 0.20 NR NR NR NR NR Tofa 10 64 58 -1.3 0.23 NR NR NR NR NR ADA 76 68 -1.5 0.21 NR NR NR NR NR PBO  Tofa 5 31 27 -1.4 0.31 NR NR NR NR NR PBO  Tofa 10 34 29 -1.7 0.30 NR NR NR NR NR Month 12 Tofa 5 74 67 -1.7 0.19 NR NR NR NR NR Tofa 10 64 56 -1.6 0.21 NR NR NR NR NR ADA 76 67 -1.6 0.20 NR NR NR NR NR PBO  Tofa 5 31 24 -1.4 0.30 NR NR NR NR NR PBO  Tofa 10 34 29 -1.9 0.28 NR NR NR NR NR Subjects with Baseline LEI = 0 were excluded from the LEI analysis. Number of subjects in FAS with LEI Baseline score >0 for tofacitinib 5 mg BID: 75; tofacitinib 10 mg BID: 64; adalimumab 40 mg SC q 2 weeks: 76; placebo: 65; placebotofacitinib 5 mg BID: 31; placebotofacitinib 10 mg BID: 34. Two separate analyses were performed. The results for Month 1 and Month 3 were generated using a MMRM including data from Month 1 to Month 3 (combined placebo). The results for Month 6 to Month 12 were generated using a MMRM including data from Month 1 to Month 12 (separate placebo treatment sequences; discarding the results for Month 1 to Month 3). Each model included the fixed effects of treatment, visit, treatment by visit interaction, geographic location and Baseline value; an unstructured covariance matrix was used. P-values are nominal. Table 19. Statistical Analysis (Repeated Measures Model) of ∆LEI at Months 1, 3, 6, 9, and 12 (for Subjects With Baseline LEI Score >0 in FAS, No Imputation) – Treatment Comparisons Visit Treatment N n LS Mean SE Difference (Active – Placebo) Difference SE of 95% CI P-value Difference Lower Upper Abbreviations: ∆ = change from Baseline; ADA = adalimumab 40 mg SC q 2 weeks; BID = twice daily; CI = confidence interval; FAS = Full Analysis Set; LEI = Leeds Enthesitis Index; LS Mean = least squares mean; MMRM = Mixed Model for Repeated Measures; N = total number of unique subjects in the longitudinal model; n = number of subjects evaluable at each visit; NR = not reported; PBO = placebo; q = every; SC = subcutaneous; SE = standard error; Tofa 5 = tofacitinib 5 mg BID; Tofa 10 = tofacitinib 10 mg BID. For subjects with Baseline SPARCC Enthesitis Index >0, at Month 3, tofacitinib 10 mg BID had a greater mean reduction from Baseline in SPARCC Enthesitis Index than placebo, but tofacitinib 5 mg BID did not. SPARCC Enthesitis Index continued to decrease beyond the 3-month, placebo-controlled period and appeared to plateau between 6 and 12 months. SPARCC Enthesitis Index for both tofacitinib dose treatment sequences appeared similar at Month 12 (Table 20). Table 20. Statistical Analysis (Repeated Measures Model) of ∆SPARCC Enthesitis Index At Months 1, 3, 6, 9, and 12 (for Subjects With Baseline SPARCC Score >0 in FAS, No Imputation) – Treatment Comparisons Visit Treatment N n LS Mean SE Difference (Active – Placebo) Difference SE of 95% CI P-value Difference Lower Upper Month 1 Tofa 5 80 79 -0.83 0.317 -0.25 0.394 -1.03 0.52 0.5230 Tofa 10 81 80 -1.27 0.321 -0.69 0.394 -1.47 0.08 0.0802 ADA 82 80 -0.95 0.336 -0.37 0.389 -1.14 0.39 0.3381 PBO 79 78 -0.58 0.355 Month 3 Tofa 5 80 77 -1.84 0.363 -0.67 0.462 -1.58 0.24 0.1488 Tofa 10 81 79 -2.41 0.364 -1.25 0.461 -2.15 -0.34 0.0072 ADA 82 79 -1.90 0.375 -0.73 0.458 -1.63 0.17 0.1106 PBO 79 78 -1.17 0.393 Month 6 Tofa 5 80 76 -2.4 0.34 NR NR NR NR NR Tofa 10 81 78 -2.6 0.34 NR NR NR NR NR ADA 82 76 -2.3 0.35 NR NR NR NR NR PBO  Tofa 5 38 33 -2.4 0.50 NR NR NR NR NR PBO  Tofa 10 41 39 -2.5 0.48 NR NR NR NR NR Month 9 Tofa 5 80 75 -2.9 0.31 NR NR NR NR NR Tofa 10 81 75 -2.6 0.32 NR NR NR NR NR ADA 82 73 -3.0 0.33 NR NR NR NR NR PBO  Tofa 5 38 34 -2.8 0.46 NR NR NR NR NR PBO  Tofa 10 41 37 -3.2 0.44 NR NR NR NR NR Month 12 Tofa 5 80 72 -3.2 0.33 NR NR NR NR NR Tofa 10 81 73 -3.1 0.33 NR NR NR NR NR ADA 82 72 -2.8 0.35 NR NR NR NR NR PBO  Tofa 5 38 31 -2.5 0.49 NR NR NR NR NR PBO  Tofa 10 41 37 -3.2 0.46 NR NR NR NR NR Subjects with Baseline SPARCC Enthesitis Index = 0 were excluded from the SPARCC Enthesitis Index analysis. Number of subjects in FAS with SPARCC Enthesitis Index Baseline score >0 for tofacitinib 5 mg BID: 81; tofacitinib 10 mg BID: 81; adalimumab 40 mg SC q 2 Weeks: 82; placebotofacitinib 5 mg BID: 38; placebotofacitinib 10 mg BID: 41. Two separate analyses were performed. The results for Month 1 and Month 3 were generated using a MMRM including data from Month 1 to Month 3 (combined placebo). The results for Month 6 to Month 12 were generated using a MMRM including data from Month 1 to Month 12 (separate placebo treatment sequences; discarding the results for Month 1 to Month 3). Each model included the fixed effects of treatment, visit, treatment by visit interaction, geographic location and Baseline value; an unstructured covariance matrix was used. P-values are nominal. Table 20. Statistical Analysis (Repeated Measures Model) of ∆SPARCC Enthesitis Index At Months 1, 3, 6, 9, and 12 (for Subjects With Baseline SPARCC Score >0 in FAS, No Imputation) – Treatment Comparisons Visit Treatment N n LS Mean SE Difference (Active – Placebo) Difference SE of 95% CI P-value Difference Lower Upper Abbreviations: ∆ = change from Baseline; ADA = adalimumab 40 mg SC q 2 weeks; BID = twice daily; CI = confidence interval; FAS = Full Analysis Set; LS Mean = least squares mean; MMRM = Mixed Model for Repeated Measures; N = total number of unique subjects in the longitudinal model; n = number of subjects evaluable at each visit; NR = not reported; PBO = placebo; q = every; SC = subcutaneous; SE = standard error; SPARCC = Spondyloarthritis Research Consortium of Canada; Tofa 5 = tofacitinib 5 mg BID; Tofa 10 = tofacitinib 10 mg BID. Mean increases from Baseline in SF-36v2 Physical Functioning Domain, Physical Component, Bodily Pain Domain, and Vitality Domain in both tofacitinib doses were higher than that of placebo at Month 3. Mean increases from Baseline in SF-36v2 Physical Functioning Domain, Physical Component, Bodily Pain Domain, and Vitality Domain in both tofacitinib doses were similar at Month 12 (Table 21). Table 21. Statistical Analysis (Repeated Measures Model) of ∆SF-36v2 Physical and Mental Component Summary and Domain Scores at Months 1, 3, 6, 9, and 12 (FAS, No Imputation) – Treatment Comparisons Visit Treatment N n LS Mean SE Difference (Active – Placebo) Difference SE of 95% CI Difference Difference Lower Upper SF-36v2 Physical Functioning Domain Month 1 Tofa 5 106 105 2.43 0.768 1.34 0.995 -0.62 3.29 0.1798 Tofa 10 104 103 3.89 0.776 2.79 0.995 0.83 4.75 0.0053 ADA 106 104 2.81 0.787 1.71 0.986 -0.23 3.65 0.0833 PBO 104 103 1.10 0.840 Month 3 Tofa 5 106 102 5.17 0.846 3.11 1.112 0.93 5.30 0.0054 Tofa 10 104 103 5.23 0.848 3.17 1.108 0.99 5.35 0.0045 ADA 106 101 5.22 0.862 3.16 1.104 0.99 5.33 0.0044 PBO 104 102 2.06 0.910 Month 6 Tofa 5 106 100 7.02 0.897 NR NR NR NR NR Tofa 10 104 100 6.15 0.900 NR NR NR NR NR ADA 106 99 6.36 0.912 NR NR NR NR NR PBO  Tofa 5 52 48 5.22 1.276 NR NR NR NR NR PBO  Tofa 10 52 48 5.22 1.291 NR NR NR NR NR Month 9 Tofa 5 106 99 7.43 0.902 NR NR NR NR NR Tofa 10 104 97 6.67 0.909 NR NR NR NR NR ADA 106 96 7.01 0.921 NR NR NR NR NR PBO  Tofa 5 52 47 5.69 1.285 NR NR NR NR NR PBO  Tofa 10 52 46 6.25 1.306 NR NR NR NR NR Month 12 Tofa 5 106 96 7.67 0.899 NR NR NR NR NR Tofa 10 104 96 7.11 0.903 NR NR NR NR NR ADA 106 94 6.81 0.917 NR NR NR NR NR PBO  Tofa 5 52 44 6.49 1.292 NR NR NR NR NR PBO  Tofa 10 52 44 4.77 1.308 NR NR NR NR NR SF-36v2 Physical Component Summary Month 1 Tofa 5 106 105 3.39 0.638 1.86 0.824 0.24 3.48 0.0247 Tofa 10 104 103 4.66 0.645 3.13 0.826 1.50 4.75 0.0002 ADA 106 104 4.00 0.655 2.46 0.817 0.85 4.07 0.0028 PBO 104 103 1.54 0.700 Table 21. Statistical Analysis (Repeated Measures Model) of ∆SF-36v2 Physical and Mental Component Summary and Domain Scores at Months 1, 3, 6, 9, and 12 (FAS, No Imputation) – Treatment Comparisons Visit Treatment N n LS Mean SE Difference (Active – Placebo) Difference SE of 95% CI Difference Difference Lower Upper Month 3 Tofa 5 106 102 5.51 0.733 2.83 0.966 0.94 4.73 0.0035 Tofa 10 104 103 5.69 0.735 3.01 0.965 1.11 4.90 0.0020 ADA 106 100 6.23 0.748 3.55 0.962 1.66 5.44 0.0003 PBO 104 102 2.68 0.785 Month 6 Tofa 5 106 100 6.72 0.773 NR NR NR NR NR Tofa 10 104 100 6.70 0.777 NR NR NR NR NR ADA 106 98 6.26 0.788 NR NR NR NR NR PBO  Tofa 5 52 48 5.86 1.101 NR NR NR NR NR PBO  Tofa 10 52 48 6.07 1.112 NR NR NR NR NR Month 9 Tofa 5 106 99 7.52 0.781 NR NR NR NR NR Tofa 10 104 97 7.21 0.787 NR NR NR NR NR ADA 106 95 6.91 0.798 NR NR NR NR NR PBO  Tofa 5 52 47 6.16 1.115 NR NR NR NR NR PBO  Tofa 10 52 46 7.15 1.130 NR NR NR NR NR Month 12 Tofa 5 106 96 7.61 0.806 NR NR NR NR NR Tofa 10 104 96 7.67 0.810 NR NR NR NR NR ADA 106 94 6.74 0.822 NR NR NR NR NR PBO  Tofa 5 52 44 5.82 1.160 NR NR NR NR NR PBO  Tofa 10 52 43 5.72 1.177 NR NR NR NR NR SF-36v2 Mental Component Summary Month 1 Tofa 5 106 105 4.12 0.841 0.93 1.092 -1.21 3.08 0.3929 Tofa 10 104 103 3.63 0.849 0.45 1.095 -1.70 2.60 0.6825 ADA 106 104 2.13 0.871 -1.06 1.088 -3.20 1.08 0.3317 PBO 104 103 3.19 0.917 Month 3 Tofa 5 106 102 4.35 0.909 1.08 1.191 -1.26 3.42 0.3649 Tofa 10 104 103 4.20 0.909 0.94 1.189 -1.40 3.28 0.4304 ADA 106 100 3.13 0.938 -0.14 1.189 -2.48 2.20 0.9068 PBO 104 102 3.27 0.976 Table 21. Statistical Analysis (Repeated Measures Model) of ∆SF-36v2 Physical and Mental Component Summary and Domain Scores at Months 1, 3, 6, 9, and 12 (FAS, No Imputation) – Treatment Comparisons Visit Treatment N n LS Mean SE Difference (Active – Placebo) Difference SE of 95% CI Difference Difference Lower Upper Month 6 Tofa 5 106 100 5.70 0.927 NR NR NR NR NR Tofa 10 104 100 5.51 0.930 NR NR NR NR NR ADA 106 98 4.58 0.955 NR NR NR NR NR PBO  Tofa 5 52 48 4.50 1.319 NR NR NR NR NR PBO  Tofa 10 52 48 3.62 1.331 NR NR NR NR NR Month 9 Tofa 5 106 99 5.07 0.974 NR NR NR NR NR Tofa 10 104 97 6.20 0.982 NR NR NR NR NR ADA 106 95 3.68 1.005 NR NR NR NR NR PBO  Tofa 5 52 47 4.61 1.391 NR NR NR NR NR PBO  Tofa 10 52 46 6.03 1.409 NR NR NR NR NR Month 12 Tofa 5 106 96 4.82 1.012 NR NR NR NR NR Tofa 10 104 96 6.26 1.016 NR NR NR NR NR ADA 106 94 4.81 1.039 NR NR NR NR NR PBO  Tofa 5 52 44 4.51 1.455 NR NR NR NR NR PBO  Tofa 10 52 43 4.43 1.474 NR NR NR NR NR SF-36v2 Role-Physical Domain Month 1 Tofa 5 106 105 4.05 0.751 2.07 0.976 0.15 3.99 0.0348 Tofa 10 104 103 3.72 0.759 1.74 0.979 -0.19 3.66 0.0767 ADA 106 104 4.09 0.770 2.11 0.970 0.20 4.01 0.0303 PBO 104 103 1.98 0.820 Month 3 Tofa 5 106 102 4.45 0.801 0.82 1.048 -1.24 2.88 0.4326 Tofa 10 104 103 4.79 0.803 1.16 1.047 -0.90 3.22 0.2696 ADA 106 100 5.21 0.820 1.58 1.044 -0.47 3.63 0.1309 PBO 104 102 3.63 0.862 Month 6 Tofa 5 106 100 6.02 0.824 NR NR NR NR NR Tofa 10 104 100 5.21 0.828 NR NR NR NR NR ADA 106 99 5.48 0.840 NR NR NR NR NR PBO  Tofa 5 52 48 4.97 1.172 NR NR NR NR NR PBO  Tofa 10 52 48 5.03 1.185 NR NR NR NR NR Table 21. Statistical Analysis (Repeated Measures Model) of ∆SF-36v2 Physical and Mental Component Summary and Domain Scores at Months 1, 3, 6, 9, and 12 (FAS, No Imputation) – Treatment Comparisons Visit Treatment N n LS Mean SE Difference (Active – Placebo) Difference SE of 95% CI Difference Difference Lower Upper Month 9 Tofa 5 106 99 6.24 0.853 NR NR NR NR NR Tofa 10 104 97 6.56 0.861 NR NR NR NR NR ADA 106 96 5.79 0.872 NR NR NR NR NR PBO  Tofa 5 52 47 4.68 1.217 NR NR NR NR NR PBO  Tofa 10 52 46 6.70 1.234 NR NR NR NR NR Month 12 Tofa 5 106 96 6.21 0.888 NR NR NR NR NR Tofa 10 104 96 7.11 0.892 NR NR NR NR NR ADA 106 94 6.37 0.906 NR NR NR NR NR PBO  Tofa 5 52 44 2.98 1.279 NR NR NR NR NR PBO  Tofa 10 52 44 5.03 1.291 NR NR NR NR NR SF-36v2 Bodily Pain Domain Month 1 Tofa 5 106 105 5.53 0.777 2.09 1.010 0.11 4.08 0.0389 Tofa 10 104 103 7.16 0.786 3.72 1.012 1.73 5.71 0.0003 ADA 106 104 6.42 0.802 2.99 1.002 1.01 4.96 0.0031 PBO 104 103 3.44 0.851 Month 3 Tofa 5 106 102 7.75 0.838 3.98 1.099 1.82 6.14 0.0003 Tofa 10 104 103 8.05 0.840 4.28 1.096 2.12 6.43 0.0001 ADA 106 101 7.52 0.859 3.75 1.092 1.60 5.90 0.0007 PBO 104 102 3.77 0.903 Month 6 Tofa 5 106 100 7.76 0.985 NR NR NR NR NR Tofa 10 104 100 10.65 0.989 NR NR NR NR NR ADA 106 99 7.76 1.004 NR NR NR NR NR PBO  Tofa 5 52 48 8.55 1.405 NR NR NR NR NR PBO  Tofa 10 52 48 8.98 1.425 NR NR NR NR NR Month 9 Tofa 5 106 99 9.03 0.953 NR NR NR NR NR Tofa 10 104 97 10.13 0.960 NR NR NR NR NR ADA 106 96 8.59 0.977 NR NR NR NR NR PBO  Tofa 5 52 47 8.46 1.362 NR NR NR NR NR PBO  Tofa 10 52 46 10.81 1.389 NR NR NR NR NR Table 21. Statistical Analysis (Repeated Measures Model) of ∆SF-36v2 Physical and Mental Component Summary and Domain Scores at Months 1, 3, 6, 9, and 12 (FAS, No Imputation) – Treatment Comparisons Visit Treatment N n LS Mean SE Difference (Active – Placebo) Difference SE of 95% CI Difference Difference Lower Upper Month 12 Tofa 5 106 96 9.15 0.961 NR NR NR NR NR Tofa 10 104 96 11.38 0.965 NR NR NR NR NR ADA 106 94 9.18 0.984 NR NR NR NR NR PBO  Tofa 5 52 44 8.59 1.384 NR NR NR NR NR PBO  Tofa 10 52 43 8.61 1.413 NR NR NR NR NR SF-36v2 General Health Domain Month 1 Tofa 5 106 105 3.29 0.610 1.14 0.785 -0.40 2.68 0.1471 Tofa 10 104 103 3.87 0.616 1.72 0.787 0.18 3.27 0.0291 ADA 106 104 1.96 0.625 -0.19 0.779 -1.72 1.34 0.8079 PBO 104 103 2.15 0.666 Month 3 Tofa 5 106 102 4.09 0.700 1.45 0.921 -0.36 3.26 0.1169 Tofa 10 104 103 3.95 0.701 1.31 0.919 -0.50 3.11 0.1560 ADA 106 101 4.73 0.713 2.08 0.916 0.28 3.89 0.0234 PBO 104 102 2.64 0.748 Month 6 Tofa 5 106 100 5.96 0.720 NR NR NR NR NR Tofa 10 104 100 4.12 0.722 NR NR NR NR NR ADA 106 99 4.81 0.733 NR NR NR NR NR PBO  Tofa 5 52 48 4.39 1.022 NR NR NR NR NR PBO  Tofa 10 52 48 3.92 1.033 NR NR NR NR NR Month 9 Tofa 5 106 99 5.93 0.773 NR NR NR NR NR Tofa 10 104 97 5.18 0.778 NR NR NR NR NR ADA 106 96 4.09 0.788 NR NR NR NR NR PBO  Tofa 5 52 47 4.72 1.102 NR NR NR NR NR PBO  Tofa 10 52 46 4.85 1.117 NR NR NR NR NR Month 12 Tofa 5 106 96 5.70 0.811 NR NR NR NR NR Tofa 10 104 96 4.63 0.815 NR NR NR NR NR ADA 106 94 4.21 0.825 NR NR NR NR NR PBO  Tofa 5 52 44 4.50 1.164 NR NR NR NR NR PBO  Tofa 10 52 44 4.12 1.175 NR NR NR NR NR Table 21. Statistical Analysis (Repeated Measures Model) of ∆SF-36v2 Physical and Mental Component Summary and Domain Scores at Months 1, 3, 6, 9, and 12 (FAS, No Imputation) – Treatment Comparisons Visit Treatment N n LS Mean SE Difference (Active – Placebo) Difference SE of 95% CI Difference Difference Lower Upper SF-36v2 Vitality Domain Month 1 Tofa 5 106 105 3.64 0.802 1.48 1.033 -0.55 3.51 0.1537 Tofa 10 104 103 4.59 0.806 2.43 1.038 0.39 4.47 0.0199 ADA 106 104 2.42 0.826 0.26 1.026 -1.76 2.28 0.8004 PBO 104 103 2.16 0.877 Month 3 Tofa 5 106 102 5.50 0.889 2.45 1.162 0.17 4.74 0.0354 Tofa 10 104 103 5.90 0.887 2.85 1.163 0.56 5.13 0.0148 ADA 106 101 4.93 0.909 1.88 1.157 -0.39 4.15 0.1049 PBO 104 102 3.05 0.954 Month 6 Tofa 5 106 100 6.81 0.969 NR NR NR NR NR Tofa 10 104 100 7.41 0.970 NR NR NR NR NR ADA 106 99 5.05 0.989 NR NR NR NR NR PBO  Tofa 5 52 48 5.34 1.378 NR NR NR NR NR PBO  Tofa 10 52 48 4.62 1.394 NR NR NR NR NR Month 9 Tofa 5 106 99 6.09 1.017 NR NR NR NR NR Tofa 10 104 97 7.82 1.023 NR NR NR NR NR ADA 106 96 5.27 1.041 NR NR NR NR NR PBO  Tofa 5 52 47 6.61 1.451 NR NR NR NR NR PBO  Tofa 10 52 46 6.39 1.472 NR NR NR NR NR Month 12 Tofa 5 106 96 7.01 1.022 NR NR NR NR NR Tofa 10 104 96 7.02 1.024 NR NR NR NR NR ADA 106 94 5.12 1.043 NR NR NR NR NR PBO  Tofa 5 52 44 5.62 1.465 NR NR NR NR NR PBO  Tofa 10 52 44 5.15 1.481 NR NR NR NR NR SF-36v2 Social Functioning Domain Month 1 Tofa 5 106 105 4.51 0.827 1.55 1.079 -0.57 3.67 0.1518 Tofa 10 104 103 4.46 0.838 1.50 1.082 -0.63 3.63 0.1663 ADA 106 104 3.34 0.852 0.37 1.073 -1.74 2.48 0.7288 PBO 104 103 2.96 0.901 Table 21. Statistical Analysis (Repeated Measures Model) of ∆SF-36v2 Physical and Mental Component Summary and Domain Scores at Months 1, 3, 6, 9, and 12 (FAS, No Imputation) – Treatment Comparisons Visit Treatment N n LS Mean SE Difference (Active – Placebo) Difference SE of 95% CI Difference Difference Lower Upper Month 3 Tofa 5 106 102 5.95 0.897 2.32 1.179 0.00 4.64 0.0496 Tofa 10 104 103 5.22 0.898 1.59 1.176 -0.72 3.91 0.1765 ADA 106 101 5.26 0.918 1.64 1.174 -0.67 3.94 0.1642 PBO 104 102 3.63 0.961 Month 6 Tofa 5 106 100 6.97 0.955 NR NR NR NR NR Tofa 10 104 100 7.08 0.959 NR NR NR NR NR ADA 106 99 7.10 0.975 NR NR NR NR NR PBO  Tofa 5 52 48 5.44 1.362 NR NR NR NR NR PBO  Tofa 10 52 48 6.05 1.373 NR NR NR NR NR Month 9 Tofa 5 106 99 7.66 0.947 NR NR NR NR NR Tofa 10 104 97 7.74 0.957 NR NR NR NR NR ADA 106 96 5.69 0.972 NR NR NR NR NR PBO  Tofa 5 52 47 5.95 1.355 NR NR NR NR NR PBO  Tofa 10 52 46 8.93 1.373 NR NR NR NR NR Month 12 Tofa 5 106 96 6.13 0.989 NR NR NR NR NR Tofa 10 104 96 8.42 0.995 NR NR NR NR NR ADA 106 94 6.32 1.012 NR NR NR NR NR PBO  Tofa 5 52 44 6.19 1.427 NR NR NR NR NR PBO  Tofa 10 52 43 6.41 1.445 NR NR NR NR NR SF-36v2 Role-Emotional Domain Month 1 Tofa 5 106 105 4.77 0.960 0.25 1.257 -2.22 2.72 0.8425 Tofa 10 104 103 3.87 0.971 -0.65 1.263 -3.13 1.83 0.6079 ADA 106 104 2.93 0.991 -1.58 1.258 -4.06 0.89 0.2094 PBO 104 103 4.52 1.042 Month 3 Tofa 5 106 102 4.21 1.010 0.53 1.326 -2.08 3.14 0.6887 Tofa 10 104 103 4.82 1.011 1.14 1.325 -1.46 3.74 0.3897 ADA 106 100 3.35 1.040 -0.33 1.329 -2.95 2.28 0.8030 PBO 104 102 3.68 1.083 Table 21. Statistical Analysis (Repeated Measures Model) of ∆SF-36v2 Physical and Mental Component Summary and Domain Scores at Months 1, 3, 6, 9, and 12 (FAS, No Imputation) – Treatment Comparisons Visit Treatment N n LS Mean SE Difference (Active – Placebo) Difference SE of 95% CI Difference Difference Lower Upper Month 6 Tofa 5 106 100 5.67 1.024 NR NR NR NR NR Tofa 10 104 100 4.68 1.027 NR NR NR NR NR ADA 106 98 4.77 1.051 NR NR NR NR NR PBO  Tofa 5 52 48 6.34 1.458 NR NR NR NR NR PBO  Tofa 10 52 48 4.56 1.473 NR NR NR NR NR Month 9 Tofa 5 106 99 5.13 1.021 NR NR NR NR NR Tofa 10 104 97 6.13 1.030 NR NR NR NR NR ADA 106 96 4.87 1.052 NR NR NR NR NR PBO  Tofa 5 52 47 5.89 1.456 NR NR NR NR NR PBO  Tofa 10 52 46 6.52 1.478 NR NR NR NR NR Month 12 Tofa 5 106 96 5.15 1.048 NR NR NR NR NR Tofa 10 104 96 6.73 1.053 NR NR NR NR NR ADA 106 94 6.03 1.075 NR NR NR NR NR PBO  Tofa 5 52 44 4.77 1.509 NR NR NR NR NR PBO  Tofa 10 52 44 4.94 1.525 NR NR NR NR NR SF-36v2 Mental Health Domain Month 1 Tofa 5 106 105 3.32 0.867 1.75 1.125 -0.46 3.96 0.1203 Tofa 10 104 103 3.87 0.874 2.30 1.129 0.08 4.52 0.0425 ADA 106 104 2.79 0.895 1.22 1.116 -0.97 3.41 0.2752 PBO 104 103 1.57 0.952 Month 3 Tofa 5 106 102 4.45 0.934 1.83 1.221 -0.57 4.23 0.1354 Tofa 10 104 103 4.23 0.932 1.62 1.220 -0.78 4.01 0.1862 ADA 106 101 3.95 0.956 1.33 1.213 -1.05 3.72 0.2731 PBO 104 102 2.62 1.009 Month 6 Tofa 5 106 100 6.11 0.951 NR NR NR NR NR Tofa 10 104 100 6.38 0.953 NR NR NR NR NR ADA 106 99 5.35 0.974 NR NR NR NR NR PBO  Tofa 5 52 48 3.70 1.354 NR NR NR NR NR PBO  Tofa 10 52 48 3.41 1.372 NR NR NR NR NR Table 21. Statistical Analysis (Repeated Measures Model) of ∆SF-36v2 Physical and Mental Component Summary and Domain Scores at Months 1, 3, 6, 9, and 12 (FAS, No Imputation) – Treatment Comparisons Visit Treatment N n LS Mean SE Difference (Active – Placebo) Difference SE of 95% CI Difference Difference Lower Upper Month 9 Tofa 5 106 99 5.79 1.022 NR NR NR NR NR Tofa 10 104 97 6.43 1.028 NR NR NR NR NR ADA 106 96 4.62 1.048 NR NR NR NR NR PBO  Tofa 5 52 47 3.57 1.461 NR NR NR NR NR PBO  Tofa 10 52 46 5.45 1.483 NR NR NR NR NR Month 12 Tofa 5 106 96 5.86 1.019 NR NR NR NR NR Tofa 10 104 96 6.58 1.022 NR NR NR NR NR ADA 106 94 5.86 1.044 NR NR NR NR NR PBO  Tofa 5 52 44 4.72 1.467 NR NR NR NR NR PBO  Tofa 10 52 44 4.48 1.483 NR NR NR NR NR In FAS, number of subjects in tofacitinib 5 mg BID: 107; tofacitinib 10 mg BID: 104; adalimumab 40 mg SC q 2 weeks: 106; placebo: 105; placebotofacitinib 5 mg BID: 52; placebotofacitinib 10 mg BID: 53. Two separate analyses were performed. The results for Month 1 and Month 3 were generated using a MMRM including data from Month 1 to Month 3 (combined placebo). The results for Month 6 to Month 12 were generated using a MMRM including data from Month 1 to Month 12 (separate placebo treatment sequences; discarding the results for Month 1 to Month 3). Each model included the fixed effects of treatment, visit, treatment by visit interaction, geographic location and Baseline value; an unstructured covariance matrix was used. P-values are nominal. Abbreviations: ∆ = change from Baseline; ADA = adalimumab 40 mg SC q 2 weeks; BID = twice daily; CI = confidence interval; FAS = Full Analysis Set; LS Mean = least squares mean; MMRM = Mixed Model for Repeated Measures; N = total number of unique subjects in the longitudinal model; n = number of subjects evaluable at each visit; NR = not reported; PBO = placebo; q = every; SC = subcutaneous; SE = standard error; SF-36 = 36-Item Short-Form Health Survey; Tofa 5 = tofacitinib 5 mg BID; Tofa 10 = tofacitinib 10 mg BID; v = version. Greater mean improvements from Baseline in EQ-5D Domains of Mobility and Pain/Discomfort, Subjects Health State Today were observed in both tofacitinib dose treatment groups (5 mg BID and 10 mg BID) than placebo at Month 3. Mean improvements from Baseline in EQ-5D Domains of Mobility and Pain/Discomfort, Subjects Health State Today in both tofacitinib doses were similar at Month 12 (Table 22). Table 22. Statistical Analysis (Repeated Measures Model) of ∆EQ-5D Domain Scores and VAS (mm) at Months 1, 3, 6, 9, and 12 (FAS, No Imputation) - Treatment Comparisons Visit Treatment N n LS Mean SE Difference (Active – placebo) Difference SE of 95% CI P-value Difference Lower Upper Mobility Month 1 Tofa 5 106 105 -0.07 0.042 0.03 0.055 -0.08 0.14 0.5805 Tofa 10 104 103 -0.19 0.043 -0.09 0.055 -0.20 0.02 0.1000 ADA 106 104 -0.15 0.043 -0.05 0.055 -0.16 0.06 0.3771 PBO 104 103 -0.10 0.046 Month 3 Tofa 5 106 101 -0.28 0.047 -0.17 0.062 -0.29 -0.05 0.0060 Tofa 10 104 103 -0.27 0.047 -0.16 0.062 -0.28 -0.04 0.0095 ADA 106 101 -0.29 0.048 -0.18 0.061 -0.30 -0.06 0.0040 PBO 104 102 -0.11 0.050 Month 6 Tofa 5 106 100 -0.3 0.05 NR NR NR NR NR Tofa 10 104 100 -0.3 0.05 NR NR NR NR NR ADA 106 99 -0.2 0.05 NR NR NR NR NR PBO  Tofa 5 52 48 -0.3 0.07 NR NR NR NR NR PBO  Tofa 10 52 48 -0.2 0.07 NR NR NR NR NR Month 9 Tofa 5 106 99 -0.3 0.05 NR NR NR NR NR Tofa 10 104 97 -0.3 0.05 NR NR NR NR NR ADA 106 96 -0.3 0.05 NR NR NR NR NR PBO  Tofa 5 52 47 -0.3 0.07 NR NR NR NR NR PBO  Tofa 10 52 46 -0.3 0.07 NR NR NR NR NR Month 12 Tofa 5 106 96 -0.3 0.05 NR NR NR NR NR Tofa 10 104 96 -0.3 0.05 NR NR NR NR NR ADA 106 94 -0.3 0.05 NR NR NR NR NR PBO  Tofa 5 52 44 -0.4 0.07 NR NR NR NR NR PBO  Tofa 10 52 44 -0.3 0.07 NR NR NR NR NR Self-Care Month 1 Tofa 5 106 105 -0.11 0.046 -0.01 0.061 -0.13 0.11 0.8375 Tofa 10 103 102 -0.16 0.047 -0.06 0.061 -0.18 0.06 0.2967 ADA 106 104 -0.16 0.047 -0.06 0.060 -0.18 0.06 0.3037 PBO 104 103 -0.09 0.050 Table 22. Statistical Analysis (Repeated Measures Model) of ∆EQ-5D Domain Scores and VAS (mm) at Months 1, 3, 6, 9, and 12 (FAS, No Imputation) - Treatment Comparisons Visit Treatment N n LS Mean SE Difference (Active – placebo) Difference SE of 95% CI P-value Difference Lower Upper Month 3 Tofa 5 106 101 -0.19 0.047 -0.07 0.062 -0.19 0.05 0.2426 Tofa 10 103 102 -0.11 0.047 0.00 0.062 -0.12 0.13 0.9370 ADA 106 101 -0.18 0.048 -0.06 0.061 -0.18 0.06 0.2990 PBO 104 102 -0.12 0.051 Month 6 Tofa 5 106 100 -0.2 0.04 NR NR NR NR NR Tofa 10 103 99 -0.3 0.05 NR NR NR NR NR ADA 106 99 -0.2 0.05 NR NR NR NR NR PBO  Tofa 5 52 48 -0.2 0.06 NR NR NR NR NR PBO  Tofa 10 52 48 -0.3 0.06 NR NR NR NR NR Month 9 Tofa 5 106 99 -0.2 0.05 NR NR NR NR NR Tofa 10 103 97 -0.2 0.05 NR NR NR NR NR ADA 106 96 -0.3 0.05 NR NR NR NR NR PBO  Tofa 5 52 47 -0.2 0.06 NR NR NR NR NR PBO  Tofa 10 52 46 -0.3 0.07 NR NR NR NR NR Month 12 Tofa 5 106 96 -0.2 0.05 NR NR NR NR NR Tofa 10 103 96 -0.3 0.05 NR NR NR NR NR ADA 106 94 -0.3 0.05 NR NR NR NR NR PBO  Tofa 5 52 44 -0.3 0.07 NR NR NR NR NR PBO  Tofa 10 52 44 -0.2 0.07 NR NR NR NR NR Usual Activities Month 1 Tofa 5 106 105 -0.17 0.043 -0.12 0.056 -0.23 -0.01 0.0365 Tofa 10 103 102 -0.19 0.043 -0.13 0.056 -0.24 -0.02 0.0181 ADA 106 104 -0.21 0.044 -0.16 0.056 -0.27 -0.05 0.0042 PBO 104 103 -0.06 0.047 Month 3 Tofa 5 106 101 -0.24 0.049 -0.07 0.064 -0.19 0.06 0.2854 Tofa 10 103 102 -0.29 0.049 -0.12 0.064 -0.25 0.01 0.0605 ADA 106 101 -0.29 0.049 -0.12 0.064 -0.25 0.00 0.0517 PBO 104 102 -0.17 0.052 Table 22. Statistical Analysis (Repeated Measures Model) of ∆EQ-5D Domain Scores and VAS (mm) at Months 1, 3, 6, 9, and 12 (FAS, No Imputation) - Treatment Comparisons Visit Treatment N n LS Mean SE Difference (Active – placebo) Difference SE of 95% CI P-value Difference Lower Upper Month 6 Tofa 5 106 100 -0.3 0.05 NR NR NR NR NR Tofa 10 103 99 -0.3 0.05 NR NR NR NR NR ADA 106 99 -0.4 0.05 NR NR NR NR NR PBO  Tofa 5 52 48 -0.3 0.07 NR NR NR NR NR PBO  Tofa 10 52 47 -0.3 0.07 NR NR NR NR NR Month 9 Tofa 5 106 99 -0.3 0.05 NR NR NR NR NR Tofa 10 103 97 -0.4 0.05 NR NR NR NR NR ADA 106 96 -0.4 0.05 NR NR NR NR NR PBO  Tofa 5 52 47 -0.3 0.07 NR NR NR NR NR PBO  Tofa 10 52 46 -0.4 0.07 NR NR NR NR NR Month 12 Tofa 5 106 96 -0.3 0.05 NR NR NR NR NR Tofa 10 103 96 -0.4 0.05 NR NR NR NR NR ADA 106 94 -0.4 0.05 NR NR NR NR NR PBO  Tofa 5 52 44 -0.3 0.07 NR NR NR NR NR PBO  Tofa 10 52 44 -0.3 0.07 NR NR NR NR NR Pain/Discomfort Month 1 Tofa 5 106 105 -0.14 0.039 -0.06 0.051 -0.17 0.04 0.2065 Tofa 10 104 103 -0.25 0.040 -0.17 0.051 -0.27 -0.07 0.0008 ADA 106 104 -0.19 0.040 -0.12 0.051 -0.22 -0.02 0.0234 PBO 104 103 -0.08 0.043 Month 3 Tofa 5 106 101 -0.25 0.044 -0.17 0.059 -0.28 -0.05 0.0046 Tofa 10 104 103 -0.27 0.044 -0.19 0.058 -0.30 -0.07 0.0014 ADA 106 101 -0.28 0.045 -0.20 0.058 -0.32 -0.09 0.0006 PBO 104 102 -0.08 0.047 Month 6 Tofa 5 106 100 -0.3 0.05 NR NR NR NR NR Tofa 10 104 100 -0.4 0.05 NR NR NR NR NR ADA 106 99 -0.3 0.05 NR NR NR NR NR PBO  Tofa 5 52 48 -0.3 0.07 NR NR NR NR NR PBO  Tofa 10 52 48 -0.4 0.07 NR NR NR NR NR Table 22. Statistical Analysis (Repeated Measures Model) of ∆EQ-5D Domain Scores and VAS (mm) at Months 1, 3, 6, 9, and 12 (FAS, No Imputation) - Treatment Comparisons Visit Treatment N n LS Mean SE Difference (Active – placebo) Difference SE of 95% CI P-value Difference Lower Upper Month 9 Tofa 5 106 99 -0.3 0.05 NR NR NR NR NR Tofa 10 104 97 -0.3 0.05 NR NR NR NR NR ADA 106 96 -0.3 0.05 NR NR NR NR NR PBO  Tofa 5 52 47 -0.4 0.07 NR NR NR NR NR PBO  Tofa 10 52 46 -0.4 0.07 NR NR NR NR NR Month 12 Tofa 5 106 96 -0.3 0.05 NR NR NR NR NR Tofa 10 104 96 -0.4 0.05 NR NR NR NR NR ADA 106 94 -0.3 0.05 NR NR NR NR NR PBO  Tofa 5 52 44 -0.2 0.07 NR NR NR NR NR PBO  Tofa 10 52 44 -0.3 0.07 NR NR NR NR NR Anxiety/Depression Month 1 Tofa 5 106 105 -0.25 0.051 -0.04 0.067 -0.17 0.09 0.5571 Tofa 10 104 103 -0.22 0.052 -0.01 0.067 -0.14 0.12 0.9080 ADA 106 104 -0.27 0.053 -0.06 0.067 -0.19 0.07 0.3830 PBO 104 103 -0.21 0.056 Month 3 Tofa 5 106 101 -0.25 0.055 -0.04 0.072 -0.18 0.10 0.5710 Tofa 10 104 103 -0.17 0.055 0.04 0.072 -0.10 0.18 0.5839 ADA 106 100 -0.32 0.056 -0.11 0.072 -0.25 0.03 0.1277 PBO 104 102 -0.21 0.059 Month 6 Tofa 5 106 100 -0.3 0.05 NR NR NR NR NR Tofa 10 104 100 -0.3 0.05 NR NR NR NR NR ADA 106 99 -0.3 0.05 NR NR NR NR NR PBO  Tofa 5 52 48 -0.3 0.08 NR NR NR NR NR PBO  Tofa 10 52 48 -0.2 0.08 NR NR NR NR NR Month 9 Tofa 5 106 99 -0.3 0.05 NR NR NR NR NR Tofa 10 104 97 -0.4 0.05 NR NR NR NR NR ADA 106 96 -0.4 0.06 NR NR NR NR NR PBO  Tofa 5 52 47 -0.2 0.08 NR NR NR NR NR PBO  Tofa 10 52 46 -0.3 0.08 NR NR NR NR NR Table 22. Statistical Analysis (Repeated Measures Model) of ∆EQ-5D Domain Scores and VAS (mm) at Months 1, 3, 6, 9, and 12 (FAS, No Imputation) - Treatment Comparisons Visit Treatment N n LS Mean SE Difference (Active – placebo) Difference SE of 95% CI P-value Difference Lower Upper Month 12 Tofa 5 106 96 -0.3 0.05 NR NR NR NR NR Tofa 10 104 96 -0.4 0.05 NR NR NR NR NR ADA 106 94 -0.4 0.06 NR NR NR NR NR PBO  Tofa 5 52 44 -0.3 0.08 NR NR NR NR NR PBO  Tofa 10 52 44 -0.3 0.08 NR NR NR NR NR VAS Score (mm) on the Subjects Health Care State Today Month 1 Tofa 5 106 105 10.75 1.859 4.16 2.421 -0.60 8.92 0.0863 Tofa 10 104 103 10.81 1.880 4.22 2.428 -0.55 8.99 0.0828 ADA 106 104 10.27 1.917 3.69 2.408 -1.05 8.42 0.1266 PBO 104 103 6.59 2.027 Month 3 Tofa 5 106 101 14.00 2.100 7.63 2.773 2.18 13.08 0.0062 Tofa 10 104 103 15.83 2.092 9.46 2.761 4.03 14.89 0.0007 ADA 106 101 13.10 2.138 6.73 2.757 1.31 12.15 0.0151 PBO 104 101 6.37 2.242 Month 6 Tofa 5 106 100 19.5 2.08 NR NR NR NR NR Tofa 10 104 100 15.7 2.09 NR NR NR NR NR ADA 106 99 15.5 2.12 NR NR NR NR NR PBO  Tofa 5 52 48 14.7 2.97 NR NR NR NR NR PBO  Tofa 10 52 48 16.6 3.00 NR NR NR NR NR Month 9 Tofa 5 106 99 19.2 2.21 NR NR NR NR NR Tofa 10 104 97 15.9 2.23 NR NR NR NR NR ADA 106 96 18.2 2.26 NR NR NR NR NR PBO  Tofa 5 52 47 12.8 3.16 NR NR NR NR NR PBO  Tofa 10 52 46 21.5 3.21 NR NR NR NR NR Month 12 Tofa 5 106 96 20.7 2.09 NR NR NR NR NR Tofa 10 104 96 19.8 2.09 NR NR NR NR NR ADA 106 94 16.5 2.14 NR NR NR NR NR PBO  Tofa 5 52 44 16.0 3.02 NR NR NR NR NR PBO  Tofa 10 52 44 19.8 3.05 NR NR NR NR NR In FAS, number of subjects in tofacitinib 5 mg BID: 107; tofacitinib 10 mg BID: 104; adalimumab 40 mg SC q 2 weeks: 106; placebo: 105; placebotofacitinib 5 mg BID: 52; placebotofacitinib 10 mg BID: 53. Table 22. Statistical Analysis (Repeated Measures Model) of ∆EQ-5D Domain Scores and VAS (mm) at Months 1, 3, 6, 9, and 12 (FAS, No Imputation) - Treatment Comparisons Visit Treatment N n LS Mean SE Difference (Active – placebo) Difference SE of 95% CI P-value Difference Lower Upper Two separate analyses were performed. The results for Month 1 and Month 3 were generated using a MMRM including data from Month 1 to Month 3 (combined placebo). The results for Month 6 to Month 12 were generated using a MMRM including data from Month 1 to Month 12 (separate placebo treatment sequences; discarding the results for Month 1 to Month 3). Each model included the fixed effects of treatment, visit, treatment by visit interaction, geographic location and Baseline value; an unstructured covariance matrix was used. P-values are nominal. Abbreviations: ∆ = change from Baseline; ADA = adalimumab 40 mg SC q 2 weeks; BID = twice daily; CI = confidence interval; EQ-5D = EuroQol-5 Dimension Health State Profile; FAS = Full Analysis Set; LS Mean = least squares mean; MMRM = Mixed Model for Repeated Measures; N = total number of unique subjects in the longitudinal model; n = number of subjects evaluable at each visit; NR = not reported; PBO = placebo; q = every; SC = subcutaneous; SE = standard error; Tofa 5 = tofacitinib 5 mg BID; Tofa 10 = tofacitinib 10 mg BID; VAS = Visual Analog Scale. Mean increases from Baseline in FACIT-F (total score, experience domain score, and impact domain score) of both tofacitinib dose treatment groups (5 mg BID and 10 mg BID) were higher than placebo at Month 3. Mean increases from Baseline in FACIT-F (total score, experience domain score, and impact domain score) in both tofacitinib doses were similar at Month 12 (Table 23). Table 23. Statistical Analysis (Repeated Measures Model) of ∆FACIT-F Total Score and Domain Scores at Months 1, 3, 6, 9, and 12 (FAS, No Imputation) - Treatment Comparisons Visit Treatment N n LS Mean SE Difference (Active – Placebo) Difference SE of 95% CI P-value Difference Lower Upper Total Score Month 1 Tofa 5 106 105 5.2 0.77 2.6 0.99 0.6 4.5 0.0106 Tofa 10 104 103 4.4 0.78 1.7 1.00 -0.3 3.6 0.0935 ADA 106 104 4.2 0.79 1.5 0.99 -0.5 3.4 0.1367 PBO 104 103 2.7 0.84 Month 3 Tofa 5 106 102 7.0 0.85 3.7 1.11 1.5 5.9 0.0010 Tofa 10 104 102 6.0 0.85 2.7 1.11 0.5 4.8 0.0164 ADA 106 101 6.0 0.87 2.6 1.10 0.5 4.8 0.0169 PBO 104 102 3.3 0.91 Month 6 Tofa 5 106 100 7.9 0.89 NR NR NR NR NR Tofa 10 104 100 8.0 0.89 NR NR NR NR NR ADA 106 99 6.5 0.91 NR NR NR NR NR PBO  Tofa 5 52 48 6.5 1.26 NR NR NR NR NR PBO  Tofa 10 52 48 7.2 1.28 NR NR NR NR NR Month 9 Tofa 5 106 99 7.9 0.92 NR NR NR NR NR Tofa 10 104 97 7.4 0.92 NR NR NR NR NR ADA 106 96 6.5 0.94 NR NR NR NR NR PBO  Tofa 5 52 47 5.5 1.31 NR NR NR NR NR PBO  Tofa 10 52 46 8.4 1.33 NR NR NR NR NR Month 12 Tofa 5 106 96 8.5 0.95 NR NR NR NR NR Tofa 10 104 96 8.4 0.95 NR NR NR NR NR ADA 106 94 6.9 0.97 NR NR NR NR NR PBO  Tofa 5 52 44 5.7 1.36 NR NR NR NR NR PBO  Tofa 10 52 44 7.6 1.38 NR NR NR NR NR Experience Domain Score Month 1 Tofa 5 106 105 2.4 0.35 1.2 0.45 0.3 2.0 0.0103 Tofa 10 104 103 2.1 0.35 0.9 0.45 -0.0 1.8 0.0556 ADA 106 104 2.1 0.36 0.9 0.45 -0.0 1.7 0.0515 PBO 104 103 1.2 0.38 Table 23. Statistical Analysis (Repeated Measures Model) of ∆FACIT-F Total Score and Domain Scores at Months 1, 3, 6, 9, and 12 (FAS, No Imputation) - Treatment Comparisons Visit Treatment N n LS Mean SE Difference (Active – Placebo) Difference SE of 95% CI P-value Difference Lower Upper Month 3 Tofa 5 106 102 3.3 0.38 1.7 0.50 0.7 2.7 0.0006 Tofa 10 104 102 2.8 0.38 1.3 0.50 0.3 2.2 0.0122 ADA 106 101 2.9 0.39 1.3 0.50 0.3 2.3 0.0081 PBO 104 102 1.6 0.41 Month 6 Tofa 5 106 100 3.6 0.40 NR NR NR NR NR Tofa 10 104 100 3.3 0.40 NR NR NR NR NR ADA 106 99 3.2 0.41 NR NR NR NR NR PBO  Tofa 5 52 48 3.0 0.57 NR NR NR NR NR PBO  Tofa 10 52 48 3.3 0.58 NR NR NR NR NR Month 9 Tofa 5 106 99 3.6 0.42 NR NR NR NR NR Tofa 10 104 97 3.3 0.42 NR NR NR NR NR ADA 106 96 3.3 0.43 NR NR NR NR NR PBO  Tofa 5 52 47 2.7 0.59 NR NR NR NR NR PBO  Tofa 10 52 46 3.9 0.60 NR NR NR NR NR Month 12 Tofa 5 106 96 3.9 0.44 NR NR NR NR NR Tofa 10 104 96 3.7 0.44 NR NR NR NR NR ADA 106 94 3.2 0.45 NR NR NR NR NR PBO  Tofa 5 52 44 2.7 0.63 NR NR NR NR NR PBO  Tofa 10 52 44 3.4 0.63 NR NR NR NR NR Impact Domain Score Month 1 Tofa 5 106 105 2.9 0.47 1.4 0.61 0.2 2.6 0.0246 Tofa 10 104 103 2.3 0.48 0.8 0.61 -0.4 2.0 0.1963 ADA 106 104 2.1 0.49 0.6 0.61 -0.6 1.8 0.2937 PBO 104 103 1.5 0.52 Month 3 Tofa 5 106 102 3.8 0.52 1.9 0.68 0.6 3.3 0.0046 Tofa 10 104 102 3.2 0.52 1.4 0.68 0.1 2.7 0.0412 ADA 106 101 3.2 0.53 1.3 0.67 0.0 2.7 0.0471 PBO 104 102 1.8 0.56 Table 23. Statistical Analysis (Repeated Measures Model) of ∆FACIT-F Total Score and Domain Scores at Months 1, 3, 6, 9, and 12 (FAS, No Imputation) - Treatment Comparisons Visit Treatment N n LS Mean SE Difference (Active – Placebo) Difference SE of 95% CI P-value Difference Lower Upper Month 6 Tofa 5 106 100 4.3 0.53 NR NR NR NR NR Tofa 10 104 100 4.7 0.53 NR NR NR NR NR ADA 106 99 3.4 0.54 NR NR NR NR NR PBO  Tofa 5 52 48 3.5 0.75 NR NR NR NR NR PBO  Tofa 10 52 48 4.0 0.76 NR NR NR NR NR Month 9 Tofa 5 106 99 4.3 0.55 NR NR NR NR NR Tofa 10 104 97 4.1 0.55 NR NR NR NR NR ADA 106 96 3.3 0.56 NR NR NR NR NR PBO  Tofa 5 52 47 2.8 0.78 NR NR NR NR NR PBO  Tofa 10 52 46 4.6 0.80 NR NR NR NR NR Month 12 Tofa 5 106 96 4.6 0.57 NR NR NR NR NR Tofa 10 104 96 4.7 0.57 NR NR NR NR NR ADA 106 94 3.7 0.58 NR NR NR NR NR PBO  Tofa 5 52 44 2.9 0.82 NR NR NR NR NR PBO  Tofa 10 52 44 4.3 0.82 NR NR NR NR NR In FAS, number of subjects in tofacitinib 5 mg BID: 107; tofacitinib 10 mg BID: 104; adalimumab 40 mg SC q 2 weeks: 106; placebo: 105; placebotofacitinib 5 mg BID: 52; placebotofacitinib 10 mg BID: 53. Two separate analyses were performed. The results for Month 1 and Month 3 were generated using a MMRM including data from Month 1 to Month 3 (combined placebo). The results for Month 6 to Month 12 were generated using a MMRM including data from Month 1 to Month 12 (separate placebo treatment sequences; discarding the results for Month 1 to Month 3). Each model included the fixed effects of treatment, visit, treatment by visit interaction, geographic location and Baseline value; an unstructured covariance matrix was used. P-values are nominal. Abbreviations: ∆ = change from Baseline; ADA = adalimumab 40 mg SC q 2 weeks; BID = twice daily; CI = confidence interval; FACIT-F = Functional Assessment of Chronic Illness Therapy-Fatigue; FAS = Full Analysis Set; LS Mean = least squares mean; MMRM = Mixed Model for Repeated Measures; N = total number of unique subjects in the longitudinal model; n = number of subjects evaluable at each visit; NR = not reported; PBO = placebo; q = every; SC = subcutaneous; SE = standard error; Tofa 5 = tofacitinib 5 mg BID; Tofa 10 = tofacitinib 10 mg BID. Analyses of BASDAI included only subjects with spondylitis present at screening (per Investigator assessment) and Baseline BASDAI >0 cm (77/422 [18%] of subjects). The number of subjects included in this analysis was small and the results should be interpreted with caution. At Month 3, the mean reduction from Baseline in BASDAI was greater in tofacitinib 10 mg BID than placebo. At Month 3, the mean reductions from Baseline in BASDAI were similar in tofacitinib 5 mg BID and placebo (Table 24). Table 24. Statistical Analysis (Repeated Measures Model) of ∆BASDAI at Months 1, 3, 6, 9, and 12 (for Subjects With Presence of Spondylitis at Screening and Baseline BASDAI Score >0 cm in FAS, No Imputation) – Treatment Comparisons Visit Treatment N n LS Mean SE Difference (Active – Placebo) Difference SE of 95% CI P-value Difference Lower Upper Month 1 Tofa 5 24 24 -1.23 0.537 0.05 0.478 -0.91 1.00 0.9210 Tofa 10 21 21 -1.60 0.508 -0.32 0.491 -1.30 0.66 0.5111 ADA 10 10 -2.30 0.673 -1.02 0.607 -2.23 0.19 0.0964 PBO 22 22 -1.27 0.581 Month 3 Tofa 5 24 24 -1.83 0.579 -0.23 0.572 -1.37 0.91 0.6848 Tofa 10 21 21 -2.78 0.559 -1.18 0.589 -2.36 -0.01 0.0486 ADA 10 10 -2.93 0.753 -1.33 0.730 -2.79 0.12 0.0722 PBO 22 22 -1.60 0.624 Month 6 Tofa 5 24 23 -2.24 0.580 NR NR NR NR NR Tofa 10 21 21 -2.35 0.560 NR NR NR NR NR ADA 10 10 -3.58 0.758 NR NR NR NR NR PBO  Tofa 5 10 9 -2.85 0.778 NR NR NR NR NR PBO  Tofa 10 12 11 -3.31 0.744 NR NR NR NR NR Month 9 Tofa 5 24 23 -2.06 0.575 NR NR NR NR NR Tofa 10 21 20 -2.71 0.558 NR NR NR NR NR ADA 10 10 -2.66 0.747 NR NR NR NR NR PBO  Tofa 5 10 9 -3.00 0.770 NR NR NR NR NR PBO  Tofa 10 12 9 -3.35 0.761 NR NR NR NR NR Month 12 Tofa 5 24 23 -2.50 0.594 NR NR NR NR NR Tofa 10 21 19 -3.30 0.587 NR NR NR NR NR ADA 10 10 -2.42 0.779 NR NR NR NR NR PBO  Tofa 5 10 9 -2.31 0.808 NR NR NR NR NR PBO  Tofa 10 12 9 -2.67 0.806 NR NR NR NR NR Number of subjects in FAS with presence of spondylitis at screening and Baseline BASDAI score >0 cm for tofacitinib 5 mg BID: 24; tofacitinib 10 mg BID: 21; adalimumab 40 mg SC q 2 weeks: 10; placebo: 22; placebotofacitinib 5 mg BID: 10; placebotofacitinib 10 mg BID: 12. Subjects with absence of spondylitis at screening or Baseline BASDAI = 0 were excluded from the analysis. Table 24. Statistical Analysis (Repeated Measures Model) of ∆BASDAI at Months 1, 3, 6, 9, and 12 (for Subjects With Presence of Spondylitis at Screening and Baseline BASDAI Score >0 cm in FAS, No Imputation) – Treatment Comparisons Visit Treatment N n LS Mean SE Difference (Active – Placebo) Difference SE of 95% CI P-value Difference Lower Upper Two separate analyses were performed. The results for Month 1 and Month 3 were generated using a MMRM including data from Month 1 to Month 3 (combined placebo). The results for Month 6 to Month 12 were generated using a MMRM including data from Month 1 to Month 12 (separate placebo treatment sequences; discarding the results for Month 1 to Month 3). Each model included the fixed effects of treatment, visit, treatment by visit interaction, geographic location and Baseline value; an unstructured covariance matrix was used. P-values are nominal. Abbreviations: ∆ = change from Baseline; ADA = adalimumab 40 mg SC q 2 weeks; BASDAI = Bath Ankylosing Spondylitis Disease Activity Index; BID = twice daily; FAS = Full Analysis Set; CI = confidence interval; LS Mean = least squares mean; MMRM = Mixed Model for Repeated Measures; N = total number of unique subjects in the longitudinal model; n = number of subjects evaluable at each visit; NR = not reported; PBO = placebo; q = every; SC = subcutaneous; SE = standard error; Tofa 5 = tofacitinib 5 mg BID; Tofa 10 = tofacitinib 10 mg BID. A summary of non-serious TEAEs (all causalities and treatment-related) up to Month 12 in >5% of subjects in any treatment sequence is provided in Table 25. A summary of all treatment-emergent serious AEs (SAEs, all causalities and treatment-related) up to Month 12 is provided in Table 26. Overall rates of TEAEs (66.4%, 71.2% and 71.7% for tofacitinib 5 mg BID, tofacitinib 10 mg BID and ablimumab 40 mg SC q2 Weeks, respectively) and SAEs (Table 26) were similar for active treatments over 12 months. For non-serious TEAEs that occurred in >5% of subjects in any treatment sequence, the incidence was numerically higher for tofacitinib 10 mg, placebotofacitinib 10 mg, and adalimumab treatment sequences versus tofacitinib 5 mg and placebotofacitinib 5 mg treatment sequences. A total of 28 subjects experienced SAEs up to Month 12. Rates of SAEs were low in all treatment sequences (<10%). Permanent discontinuations due to AEs were low in all treatment sequences (<6%, Table 4). One subject (placebotofacitinib 5 mg BID treatment sequence) died during the double- blind treatment period after Month 3 (on tofacitinib 5 mg treatment for a total of 29 days) due to Cardiac arrest. The event was considered not related to study drug. Table 25. Treatment-Emergent Non-Serious Adverse Events by System Organ Class and Preferred Term Up to Month 12 in >5% of Subjects in Any Treatment Sequence (All Causalities and Treatment-Related) - Safety Analysis Set Adalimumab Placebo  Placebo  System Organ Class Tofacitinib Tofacitinib 40 mg SC Tofacitinib 5 mg Tofacitinib 10 mg Preferred Term 5 mg BID 10 mg BID q 2 Weeks BID BID n (%) n1 n2 n (%) n1 n2 n (%) n1 n2 n (%) n1 n2 n (%) n1 n2 Evaluable for AEs 107 104 106 52 53 With AEs 31 (28.97) 43 (41.35) 43 (40.57) 15 (28.85) 22 (41.51) Gastrointestinal disorders 4 (3.74) 4 2 5 (4.81) 5 1 7 (6.60) 8 6 0 0 0 4 (7.55) 7 1 Abdominal pain 1 (0.93) 1 1 1 (0.96) 1 0 2 (1.89) 2 1 0 0 0 3 (5.66) 4 1 Nausea 3 (2.80) 3 1 4 (3.85) 4 1 6 (5.66) 6 5 0 0 0 1 (1.89) 3 0 Infections and infestations 21 (19.63) 31 15 29 (27.88) 35 15 27 (25.47) 36 23 8 (15.38) 11 8 12 (22.64) 17 6 Nasopharyngitis 8 (7.48) 9 3 12 (11.54) 13 6 11 (10.38) 14 8 4 (7.69) 5 3 4 (7.55) 4 0 Pharyngitis 5 (4.67) 5 2 6 (5.77) 6 3 7 (6.60) 9 7 0 0 0 3 (5.66) 3 2 Upper respiratory tract 10 (9.35) 13 7 11 (10.58) 11 6 8 (7.55) 9 5 5 (9.62) 5 4 5 (9.43) 6 2 infection Urinary tract infection 2 (187) 4 3 4 (3.85) 5 0 4 (3.77) 4 3 1 (1.92) 1 1 4 (7.55) 4 2 Investigations 6 (5.61) 10 3 7 (6.73) 9 7 9 (8.49) 22 19 4 (7.69) 5 2 5 (9.43) 8 1 Alanine aminotransferase 3 (2.80) 3 1 3 (2.88) 3 3 8 (7.55) 11 9 3 (5.77) 3 1 1 (1.89) 1 0 increased Aspartate aminotransferase 0 0 0 1 (0.96) 1 1 7 (6.60) 8 7 1 (1.92) 1 0 1 (1.89) 1 0 increased Blood creatine 5 (4.67) 7 2 5 (4.81) 5 3 3 (2.83) 3 3 1 (1.92) 1 1 5 (9.43) 6 1 phosphokinase increased Musculoskeletal and 2 (1.87) 2 0 1 (0.96) 1 0 3 (2.83 3 0 3 (5.77) 4 0 0 0 0 connective tissue disorders Spinal pain 2 (1.87) 2 0 1 (0.96) 0 0 3 (2.83) 3 0 3 (5.77) 4 0 0 0 0 Nervous system disorders 5 (4.67) 6 4 11 (10.58) 17 11 7 (6.60) 10 3 2 (3.85) 3 3 4 (7.55) 7 5 Headache 5 (4.67) 6 4 11 (10.58) 17 11 7 (6.60) 10 3 2 (3.85) 3 3 4 (7.55) 7 5 Except for ‘n1’ and n2’ subjects were only counted once per treatment for each row. MedDRA (v18.1) coding dictionary applied. Abbreviations: AE = adverse event; BID = twice daily; MedDRA = Medical Dictionary for Regulatory Activities; n = number of subjects in this reporting group affected by any occurrence of this adverse event (all causalities); n1 = number of occurrences of treatment-emergent all causalities adverse events; n2 = number of occurrences of treatment-emergent causally related to treatment adverse events; q = every; SC = subcutaneous; v = version. Table 26. Treatment-Emergent Serious Adverse Events by System Organ Class and Preferred Term Up to Month 12 (All Causalities and Treatment-Related) - Safety Analysis Set System Organ Class Tofacitinib Tofacitinib Adalimumab Placebo  Placebo  Preferred Term 5 mg BID 10 mg BID 40 mg SC Tofacitinib 5 mg Tofacitinib 10 mg q 2 Weeks BID BID n (%) n1 n2 n (%) n1 n2 n (%) n1 n2 n (%) n1 n2 n (%) n1 n2 Evaluable for AEs 107 104 106 52 53 With AEs 8 (7.48) 4 (3.85) 9 (8.49) 3 (5.77) 4 (7.55) Cardiac Disorders 0 0 0 0 0 0 2 (1.89) 2 0 1 (1.92) 1 0 0 0 0 Atrial fibrillation 0 0 0 0 0 0 1 (0.94) 1 0 0 0 0 0 0 0 Bradycardia 0 0 0 0 0 0 1 (0.94) 1 0 0 0 0 0 0 0 Cardiac arrest 0 0 0 0 0 0 0 0 0 1 (1.92) 1 0 0 0 0 Gastrointestinal disorders 1 (0.93) 1 0 0 0 0 1 (0.94) 1 0 0 0 0 2 (3.77) 2 0 Abdominal hernia 0 0 0 0 0 0 0 0 0 0 0 0 1 (1.89) 1 0 Chronic gastritis 0 0 0 0 0 0 1 (0.94) 1 0 0 0 0 0 Diverticulum 0 0 0 0 0 0 0 0 0 0 0 0 1 (1.89) 1 0 Nausea 1 (0.93) 1 0 0 0 0 0 0 0 0 0 0 0 0 0 Hepatobiliary disorders 0 0 0 0 0 0 1 (0.94) 1 0 0 0 0 0 0 0 Bile duct stone 0 0 0 0 0 0 1 (0.94) 1 0 0 0 0 0 0 0 Infections and infestations 0 0 0 1 (0.96) 1 0 1 (0.94) 2 0 2 (3.85) 2 2 0 0 0 Appendicitis 0 0 0 0 0 0 0 1 (1.92) 1 1 0 0 0 Herpes simplex 0 0 0 0 0 0 1 (0.94) 1 0 0 0 0 0 0 0 Influenza 0 0 0 1 (0.96) 1 0 0 0 0 0 0 0 0 0 0 Pneumonia 0 0 0 0 0 0 0 0 0 1 (1.92) 1 1 0 0 0 Pyoderma streptococcal 0 0 0 0 0 0 1 (0.94) 1 0 0 0 0 0 Injury, poisoning and procedural 1 (0.93) 1 0 0 0 0 1 (0.94) 1 0 0 0 0 0 0 0 complications Joint injury 1 (0.93) 1 0 0 0 0 1 (0.94) 1 0 0 0 0 0 0 0 Metabolism and nutrition 0 0 0 1 (0.96) 1 0 0 0 0 0 0 0 0 0 0 disorders Dehydration 0 0 0 1 (0.96) 1 0 0 0 0 0 0 0 0 0 0 Table 26. Treatment-Emergent Serious Adverse Events by System Organ Class and Preferred Term Up to Month 12 (All Causalities and Treatment-Related) - Safety Analysis Set System Organ Class Tofacitinib Tofacitinib Adalimumab Placebo  Placebo  Preferred Term 5 mg BID 10 mg BID 40 mg SC Tofacitinib 5 mg Tofacitinib 10 mg q 2 Weeks BID BID n (%) n1 n2 n (%) n1 n2 n (%) n1 n2 n (%) n1 n2 n (%) n1 n2 Evaluable for AEs 107 104 106 52 53 With AEs 8 (7.48) 4 (3.85) 9 (8.49) 3 (5.77) 4 (7.55) Musculoskeletal and connective 1 (0.93) 1 0 0 0 0 2 (1.89) 2 0 0 0 0 0 0 0 tissue disorders Intervertebral disc disorder 0 0 0 0 0 0 1 (0.94) 1 0 0 0 0 1 (1.89) 1 0 Musculoskeletal chest pain 0 0 0 0 0 0 1 (0.94) 1 0 0 0 0 0 0 0 Psoriatic arthropathy 1 (0.93) 1 0 0 0 0 0 0 0 0 0 0 0 0 0 Spondylolisthesis 0 0 0 0 0 0 0 0 0 0 0 0 1 (1.89) 1 0 Neoplasms benign, malignant and 3 (2.80) 4 0 0 0 0 0 0 0 0 0 0 0 0 0 unspecified (incl cysts and polyps) Bladder transitional cell 1 (0.93) 1 0 0 0 0 0 0 0 0 0 0 0 0 0 carcinoma Infected neoplasm 1 (0.93) 1 0 0 0 0 0 0 0 0 0 0 0 0 0 Invasive ductal breast carcinoma 1 (0.93) 1 0 0 0 0 0 0 0 0 0 0 0 0 0 Squamous cell carcinoma of the 1 (1.75) 1 0 0 0 0 0 0 0 0 0 0 0 0 0 vulva Nervous system disorders 1 (0.93) 1 0 0 1 (0.94) 1 0 0 0 0 0 0 0 Migraine 1 (0.93) 1 0 0 0 0 0 0 0 0 0 0 0 0 0 Transient ischaemic attack 0 0 0 0 1 (0.94) 1 0 0 0 0 0 0 0 Renal and urinary disorders 1 (0.93) 1 0 0 0 0 1 (1.89) 1 0 Calculus urinary 1 (0.93) 1 0 0 0 0 0 0 0 0 0 0 0 0 0 Nephropathy 0 0 0 0 0 0 0 0 0 0 0 0 1 (1.89) 1 0 Reproductive system and breast 0 1 (1.61) 2 0 1 (2.00) 1 0 0 0 0 1 (3.57) 1 0 disorders Cystocele 0 0 0 1 (1.61) 1 0 0 0 0 0 0 0 0 0 0 Postmenopausal haemorrhage 0 0 0 0 0 0 1 (2.00) 1 0 0 0 0 0 0 0 Rectocele 0 0 0 1 (1.61) 1 0 0 0 0 0 0 0 0 0 0 Uterine polyp 0 0 0 0 0 0 0 0 0 0 0 0 1 (3.57) 1 0 Table 26. Treatment-Emergent Serious Adverse Events by System Organ Class and Preferred Term Up to Month 12 (All Causalities and Treatment-Related) - Safety Analysis Set System Organ Class Tofacitinib Tofacitinib Adalimumab Placebo  Placebo  Preferred Term 5 mg BID 10 mg BID 40 mg SC Tofacitinib 5 mg Tofacitinib 10 mg q 2 Weeks BID BID n (%) n1 n2 n (%) n1 n2 n (%) n1 n2 n (%) n1 n2 n (%) n1 n2 Evaluable for AEs 107 104 106 52 53 With AEs 8 (7.48) 4 (3.85) 9 (8.49) 3 (5.77) 4 (7.55) Respiratory, thoracic and 0 1 (0.96) 3 0 1 (0.94) 1 0 0 0 0 0 0 0 mediastinal disorders Bronchial hyperreactivity 0 0 0 1 (0.96) 1 0 0 0 0 0 0 0 0 0 0 Bronchospasm 0 0 0 1 (0.96) 1 0 0 0 0 0 0 0 0 0 0 Dyspnoea exertional 0 0 0 0 0 0 1 (0.94) 1 0 0 0 0 0 0 0 Hypoxia 0 0 0 1 (0.96) 1 0 0 0 0 0 0 0 0 0 0 Skin and subcutaneous tissue 1 (0.93) 1 0 1 (0.93) 1 0 0 0 0 0 0 0 0 0 0 disorders Angioedema 1 (0.93) 1 0 0 0 0 0 0 0 0 0 0 0 0 0 Dermal cyst 0 0 0 1 (0.93) 1 0 0 0 0 0 0 0 0 0 0 Vascular disorders 0 0 0 1 (0.96) 1 1 0 0 0 0 0 0 1 (1.89) 1 0 Deep vein thrombosis 0 0 0 0 0 0 0 0 0 0 0 0 1 (1.89) 1 0 Hypertension 0 0 0 1 (0.96) 1 1 0 0 0 0 0 0 0 0 0 Except for n1 and n2, subjects were counted only once per treatment in each row. MedDRA (v18.1) coding dictionary applied. Abbreviations: AE = adverse event; BID = twice daily; MedDRA = Medical Dictionary for Regulatory Activities; N = number of subjects in Safety Analysis Set; n = number of subjects in this reporting group affected by any occurrence of this AE, All Causalities; n1 = number of occurrences of treatment-emergent All Causalities AEs; n2 = number of occurrences of treatment-emergent causally related to treatment AEs; q = every; SC = subcutaneous; v = version. CONCLUSIONS:  The study met the primary efficacy objectives demonstrating that both tofacitinib 5 mg BID and 10 mg BID in subjects with active PsA on background csDMARDs were superior to placebo treatment for ACR20 response and ∆HAQ-DI at Month 3.  ACR50 and ACR70 response rates demonstrated superiority of both tofacitinib doses to placebo at Month 3.  Both doses of tofacitinib were statistically significantly higher than placebo in ACR20 by Week 2 (first post-baseline assessment).  For subjects with a Baseline BSA ≥3% and PASI score >0, PASI75 response demonstrated separation of both tofacitinib doses from placebo at Month 3.  For subjects with a Baseline LEI score >0, mean reduction from Baseline in LEI of tofacitinib 10 mg BID was superior to that of placebo at Month 3, while tofacitinib 5 mg BID did not achieve statistical superiority over placebo at Month 3.  Due to the sequential nature of the statistical testing procedure employed, no statistical significance of tofacitinib from placebo can be claimed for the endpoints below at Month 3.  For subjects with a Baseline DSS score >0, mean reduction from Baseline in DSS of tofacitinib 10 mg BID was higher than that of placebo at Month 3.  The mean increases from Baseline in SF-36 Physical Functioning Domain of both tofacitinib doses were higher than that of placebo at Month 3.  The mean increases from Baseline in FACIT-F (total score, experience domain score and impact domain score) of both tofacitinib doses were higher than that of placebo at Month 3.  Subjects starting on placebo and switching to either tofacitinib dose after 3 months reached a similar level of efficacy as the study arms with active tofacitinib treatment from Baseline at Month 12.  Numerical differences were observed between tofacitinib 5 mg BID and 10 mg BID across the efficacy endpoints; however, these differences were deemed not clinically relevant when considering the totality of the efficacy data over 12 months.  Tofacitinib (5 mg BID and 10 mg BID) administered to subjects with active PsA was well tolerated. Overall rates of AEs and SAEs were similar for active treatments over 12 months. Rates of SAEs were low in all treatment sequences (<10%). Permanent discontinuations due to AEs were low in all treatment sequences (<6%). One subject died during the study (Cardiac arrest). 